Estimating the incidence of acute HIV infection from a single cross-sectional sample by Akindolani, Omotola Omokunbi
 ESTIMATING THE INCIDENCE OF ACUTE HIV 
INFECTION FROM A SINGLE CROSS-SECTIONAL 
SAMPLE 
 
 
 
 
 
 
Omotola Omokunbi Akindolani 
 
 
 
Supervisor: Prof. J. Galpin 
School of Statistics and Actuarial Science 
 
 
 
 
A research report submitted to the Faculty of Science, University of the            
Witwatersrand, Johannesburg, in partial fulfilment of the requirements for 
the degree of Master of Science. 
 
 
 
 
 
 
 
 
 
February, 2010.
i 
 
DECLARATION 
 
 
ii 
 
ABSTRACT  
 
The Human Immunodeficiency Virus (HIV) epidemic is currently one of the greatest 
challenges and most important health issues in the world. South Africa has one of the 
fastest growing epidemics in the world therefore reliable estimates of prevalence and 
incidence are required for understanding the magnitude of the epidemic and 
improving the methods of prevention.  
 
This study examines the estimation of HIV incidence from a cross-section of people, 
using one of the laboratory methods that discover recent HIV infection in blood 
samples. The incidence estimate is obtained at a single point in time, thereby saving 
time and cost expended in following a cohort over a period of time.  It also examines 
incidence from pooled blood samples, and evaluates the assumptions of the different 
methods of estimating HIV incidence, comparing each of them; and checking the 
sensitivity of the estimates to the assumptions. 
 
Results from the simulation study shows that accurate estimates of incidence can be 
obtained by pooling blood samples; and these estimates are obtained at a fraction of 
the cost of individual testing. 
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CHAPTER 1 : INTRODUCTION 
 
1.1 BACKGROUND 
 
The Human Immunodeficiency Virus (HIV) epidemic is currently one of the greatest 
challenges and most important health issues in the world. The virus needs no 
introduction, as it is the one of the deadliest diseases in the world, with no known cure 
as yet. It is spread most commonly by having unprotected sex with an infected 
partner, having contact with infected blood, sharing of needles or syringes with 
someone infected with the virus and from mothers to their babies during pregnancy, 
birth or breast feeding. 
 
Over the years, knowledge of the spread and prevention of HIV infection has 
increased considerably (Pettifor, Macphail, Rees and Cohen, 2008; UNAIDS, 2008). 
However, despite this increase in knowledge, the epidemic is still spreading at an 
alarming rate in Africa, especially in Southern Africa. UNAIDS (2008) estimates that 
by the end of 2007, there were 5.7 million South Africans who were infected with the 
virus, and this figure makes this the country with the largest HIV epidemic in the 
world.  
 
1.2 THE HIV EPIDEMIC IN SOUTH AFRICA 
 
 In addition, South Africa has one of the fastest growing epidemics in the world 
(UNAIDS, 2008), thus reliable statistics are required for understanding the magnitude 
of the epidemic and improving the methods of prevention. In order to measure how 
fast the epidemic is growing, estimates of prevalence and incidence are needed to 
determine the magnitude and rate of new infections.  
 
The first cases of the epidemic are reported to have occurred around the early 80‟s, 
and were limited to homosexual men. However the pattern soon changed and by the 
late 1980‟s, the epidemic had spread to the heterosexual population, and even the 
children, through mother-to-child transmission. The main mode of transmission of 
HIV is through sexual intercourse (Gilbert and Walker, 2002).  The spread of HIV in 
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South Africa is mainly due to heterosexual contact, with subtype C being the 
predominant subtype (Abdool Karim and Abdool Karim, 1999). 
Like most African countries, South Africa is plagued with poor quality of data on HIV 
(Williams and Gouws, 2001). However, the country and its government continue to 
try to find ways to improve on this deficiency. Data on HIV is collected from 
Voluntary Counseling and Testing (VCT) centers and Sexually Transmitted Diseases 
(STD) clinics, Family Planning Clinics and hospitals.  Williams, Gouws, Wilkinson, 
and Abdool Karim (2001) acknowledge that incidence estimates are not available in 
South Africa because of the difficulties and cost associated with obtaining these 
estimates.  
 
A number of studies have been undertaken by different bodies or research 
organisations, for the purpose of collecting data on HIV. Examples of these include: 
The Nelson Mandela/HSRC study of HIV/AIDS (Shisana and Simbayi, 2002); the 
Medical Research Council (MRC) research among sex workers in KwaZulu Natal 
(Ramjee, Abdool Karim and Sturm, 1998) and the Carletonville survey carried out on 
a sample of mineworkers living in informal settlements in Johannesburg (Gilgen, 
Campbell, Williams, Taljaard and Macphail, 2000). However, these studies only focus 
on prevalence rates. 
 
 In order to plan HIV prevention and treatment efforts, the number of infections that 
are present within a population has to be determined or estimated (Kral, Lorvick, Gee, 
Bacchetti, Rawal, Busch, and Edlin, 2003) and this can be achieved through the 
estimation of prevalence (the number of HIV positive people in the population) and 
incidence (the number of new infections in the past year or other time period).  
 
1.3 HIV PREVALENCE 
 
The UNAIDS 2008 report defines HIV prevalence as the total number of people 
living with HIV irrespective of when they were infected. HIV prevalence estimates 
are usually obtained using one of two methods: 
 
1) By monitoring sentinel populations: Sentinel surveillance is a system in which 
specific sites and population groups are selected, and a predetermined number of 
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people are routinely tested in a regular and consistent way (Nelson, 2005). Examples 
of Sentinel Populations include:  
 Pregnant women in antenatal clinics 
 STD clinic attendees 
 Blood donors 
 Tuberculosis patients and  
 Commercial sex workers.  
This is the most common method of estimation, especially in the less developed 
countries. In South Africa for instance, a national survey of HIV prevalence among 
women attending public antenatal clinics has been conducted by the Department of 
Health annually since 1990 (Department of Health, 2007). The information from these 
surveys is then used to estimate prevalence in other groups through modelling. The 
limitations of the estimates obtained from the surveys are that we cannot draw 
conclusions about certain parts of the population, such as men, non pregnant women 
and the sexually inactive. They also do not give estimates of incidence, unless the 
same people are re-tested and the person identifier is known; and this is not usually 
the case. 
 
2) By population based surveys. This method uses a nationally representative sample 
of households to determine HIV prevalence. This is done by screening a 
representative sample using an antibody test such as Enzyme Linked Immunosorbent 
Assay (ELISA), and estimating the proportion of people infected with HIV from the 
known or estimated population total (Salomon and Murray, 2001). Examples of 
population–based surveys in South Africa are those carried out by the Human 
Sciences Research Council (HSRC) in conjunction with the Nelson Mandela 
Foundation and by the MRC. 
 
Salomon and Murray (2001) note that although these surveys provide information on 
trends in the epidemic, and are more representative of the population; they have been 
undertaken in only a few developing countries. They are also very expensive to 
conduct and suffer from non-response bias due to respondents‟ refusal. 
 
Although HIV prevalence estimates are useful in determining the state of the 
epidemic, they only give us a „historical‟ perspective on the rate of infection, giving 
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us information only on what occurred in the past (Gouws, Williams, Sheppard, 
Barryett and Abdool Karim, 2002). With the high increase in HIV/AIDS related 
deaths, it is not clear whether a slowing down of the prevalence rate can be related to 
a decrease in the incidence rate, a high increase in death rate or both. 
 
1.4 HIV INCIDENCE 
 
HIV incidence is defined as the number of people who became infected with the HIV 
virus over a period of 1 year (UNAIDS, 2008). 
Incidence can be expressed in two ways: 
 Incidence rate, which is the represented by the number of incident cases 
divided by the population at risk within a specific time period in the course of 
a time period. It is also known as Incidence density. 
 Incidence risk, which is the ratio of incident cases to the population at risk at 
the beginning of the observation period. Philippe (2001) notes that it is also 
known as the cumulative incidence. 
 
HIV incidence data are less straightforward and more complex to obtain; and are 
usually estimated rather than measured directly. Research has shown that the HIV 
virus can be present in an individual without any clinical symptoms for a long time 
(Parekh and McDougal, 2005). Sometime after an individual becomes exposed to the 
HIV virus, there is a window period of 130-170 days during which HIV antibodies 
cannot be detected in the blood using standard HIV antibody tests. According to 
Rosenberg (2002), this period after infection with HIV, but before the development of 
detectable antibodies is known as Acute HIV Infection or Primary HIV infection. 
During this window period, people are usually unaware of the fact that they are 
infected, because when they go for tests, the tests are negative, yet they actually have 
the virus.  
 
Thus the challenge in obtaining incidence estimates is to establish when an individual 
first contracted the virus, and this is no easy feat. Nevertheless, some indirect methods 
of obtaining incidence estimates exist, and they include the back-calculation method, 
cohort studies and cross-sectional studies. Since this study is focused more on 
incidence than prevalence, these methods will be described in detail in the literature 
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review section. It should be noted that while the different methods are outlined, not all 
of them will be used in this study, as this study focuses on the technique based on 
pooling samples and using more than one test for HIV.  This technique involves using 
portions of blood samples submitted to a laboratory, with the person identifiers 
removed, and then testing samples obtained by pooling the blood of several patients.  
 
Laboratory methods and tests to identify recent HIV infection have improved over 
time (Parekh and McDougal, 2005). However, one main issue with using these tests is 
the cost associated with the administering of the tests. The pooling of blood samples is 
one of the mechanisms used in the reduction of the costs associated with HIV testing. 
 
Estimates of HIV incidence are used to formulate treatment plans and also help to 
examine and evaluate programs aimed at reducing the spread of the virus. When new 
cases of HIV arise in any country, this shows that the public programs to eradicate the 
epidemic are not working and more ways should be devised to educate people on the 
need for prevention (Rutherford, Schwarcz, and McFarland, 2000; Kral et al., 2003). 
 
1.5 PROBLEM STATEMENT 
 
HIV incidence estimates in South Africa, and indeed the whole of Africa, are scarce 
and mostly unreliable. Most of these estimates are obtained from cohort studies, 
which are based on studies of pregnant women (Gilbert and Walker, 2002; Williams 
et al., 2001). Thus they are non-representative of the whole population since they do 
not include men and non-pregnant women. The question now is: Are there other cost 
effective methods of estimating incidence, which do not have to depend on only a 
select group of the population? Can these methods be used without having to organise 
a cohort study? Will any of these methods provide accurate estimates, be as precise or 
even more precise as the widely used cohort method? 
 
This study examines the estimation of HIV incidence from a cross-section of people, 
using one of the laboratory methods that discover recent HIV infection in blood 
samples. Thus the incidence estimate is obtained at a single point in time, thereby 
saving time and cost expended in following a cohort over a period of time.  It also 
6 
 
examines the estimation of incidence from pooled blood samples, which provide 
accurate estimates of incidence at a lower cost than the common antenatal surveys. 
 
1.6 BACKGROUND TO THE STUDY 
 
In 2004, medical researchers from the University of the Witwatersrand, Johannesburg 
carried out a cross-sectional study to assess the prevalence of Acute HIV infection 
among South African men and women attending a primary health care clinic in 
downtown Johannesburg.  
 
Consultations between the researchers and representatives of the School of Statistics 
and Actuarial Science (University of the Witwatersrand) were set up in order to assist 
with the various concerns raised during the study. One of the concerns was the 
determination of which confidence intervals to use for the research. During the course 
of these consultations, several questions were raised with regards to the effect of 
sensitivity and specificity of the tests used, and the effect of prevalence and the 
window period on estimates of incidence. 
  
1.7 OBJECTIVES 
 
The primary objective of this research is to investigate the statistical properties of 
estimates of incidence from a cross-sectional sample, using a pooling technique. The 
other objectives are to: 
1. Evaluate the assumptions in the different methods of estimating HIV incidence, 
comparing them; and checking the sensitivity of the estimates to the assumptions. 
2. Examine the strengths, weaknesses and appropriateness of the current approaches 
to estimating the incidence of HIV. 
3. Examine the accuracy of pooling blood samples for the detection of HIV infection. 
4. Compare incidence estimates derived from individual testing and pooled testing of 
different grouping strategies, discussing the different results. 
 
In addition, an estimate of HIV incidence based on a sample from the Esselen clinic 
will be provided, as well as applying the findings from this report to the dataset from 
the clinic. 
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CHAPTER 2 : LITERATURE REVIEW 
 
This chapter provides a review of the literature around the different methods of 
estimating HIV incidence, and the advantages and disadvantages associated with each 
method. Due to the importance of cost in group testing, there will also be a detailed 
discussion on the pooling method and its application.  
 
2.1 METHODS OF ESTIMATING HIV INCIDENCE 
 
HIV incidence rates help us understand the epidemiology of HIV, and also help in the 
formulation of sound heath policies, the appropriate allocation of resources, and the 
planning of programs for the primary and secondary prevention of infection. 
Cleghorn, Jack, Murphy, Edwards, Mahabir, Paul, O‟Brien, Greenberg, Weinhold, 
Bartholomew, Brookmeyer, and Blattner (1998) note that HIV incidence is the best 
measure of the current trends of the epidemic, and very important in determining 
Acquired Immune Deficiency Syndrome (AIDS) incidence.  Despite the rise of 
infection rates all over the world, HIV incidence estimates are still difficult to obtain. 
There are different types of studies which provide estimates of HIV incidence, and 
they are discussed below. 
 
2.1.1 COHORT STUDIES 
 
A cohort study is a study in which patients who presently have exposure to a certain 
risk are followed over time (in days, weeks, months, years) through periodic and 
repeated testing, and are compared with another group who are not exposed to the risk 
under investigation (Grimes and Schulz, 2002). These studies involve repeated sample 
collection and testing of individuals at set intervals. 
 
 In a typical cohort study, groups of people called cohorts are chosen because they 
have an exposure of interest. The respondents are free of the disease of interest at the 
beginning of the study and then they are followed up through time to determine who 
develops the disease. Incidence is then estimated by dividing the number of new cases 
discovered by the number of person years of exposure (Kaplan and Brookmeyer, 
1999; Satten, Janssen, Busch, and Datta, 1999). Cohort studies are also known as 
longitudinal studies or follow up studies, and they are considered to be the best 
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method for determining the incidence and
 
natural history of a condition because it 
enables calculation of true incidence rates and relative risks (Grimes and Schulz, 
2002). 
 
Cohort studies are of different types: In a closed cohort study, subjects or respondents 
are recruited into the study, and followed up for a specific period of time. During this 
time, no new subjects may be recruited into the study, even if some subjects may be 
lost through death, withdrawal or migration (Cleghorn et al., 1998). In an open cohort, 
subjects are continually enrolled into the study, thus making the study long and 
undefined. 
 
Although cohort studies are regarded as the common approach to estimating 
incidence, they have several disadvantages and limitations. The results from the study 
may be non-representative of the whole population if they involve a select group of 
such as women attending antenatal care clinics.  
 
Brookmeyer, Quinn, Shepherd, Mehendale, Rodrigues and Bollinger (1995) note that 
this type of study is often plagued by a „follow up bias‟. Bias in cohort studies occurs 
when individuals who return for follow up have different incidence rates from those 
who do not return. This is usually because during follow up, they may have received 
counselling, and have become aware of the dangers of the disease, and therefore 
engaged in lower-risk behaviour. Follow up bias may also occur when individuals 
who are at higher risk of HIV infection do not return for follow up.  In addition, they 
are time consuming because the researchers have to wait for the conditions of interest 
to develop before arriving at a conclusion (Kaplan, Kedem, and Pollack, 1998). Other 
disadvantages are the fact that cohort studies are expensive, and difficult to undertake, 
because they require assembling and following up a large number of people. 
(Brookmeyer, 1997; Gouws et al., 2002; Parekh and McDougal, 2005).  
 
An example of a cohort study is the one conducted by Beyrer, Brookmeyer, 
Natpratan, Kunawararak, Niraroot, Palapunya, Khamboonruang, Celentano and 
Nelson (1996). The cohort study, which was conducted in Thailand, involved using 2 
different populations: commercial male sex workers and commercial female sex 
workers. The study was conducted between 1989 and 1994. 
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The results show high incidence rates of 23.8 per 100 person-years among female sex 
workers, and 11.9 per 100 among the males. However, follow up among the 
respondents was incomplete because of the high migration rates and mobility of the 
sex workers. Thus the estimates obtained from this study were based only on those 
who could be followed up. 
 
Few cohort studies have been carried out in Africa because of the outlined 
disadvantages.  
 
2.1.2 BACK-CALCULATION 
 
Estimates of HIV incidence can be obtained from AIDS incidence data through the 
method of back-calculation, or back-projection. Back-calculation is a method of 
estimation that makes inferences about the HIV incidence through the use of AIDS 
prevalence, and the distribution of the incubation period over time (Kaplan and 
Brookmeyer, 1999; Brookmeyer, 1991). The concept of back-calculation is to use the 
incubation period to work backwards and reconstruct how many people must have 
been infected to give rise to the observed pattern of AIDS cases (Brookmeyer, 1996).  
 
Since most developed countries have some form of AIDS reporting, this method of 
estimation is favoured because it makes use of readily available data on AIDS. 
According to Bacchetti, Segal, and Jewell (1993) back-calculation depends on 3 major 
factors: 
1. The incubation period: this is the time between HIV infection, and AIDS diagnosis. 
2. The number of AIDS diagnoses over time (obtained from national surveillance 
systems).   
3. A model for the distribution of infections. 
The basic equation of back-calculation is given by: 
0
( ) ( ) ( | )
t
a t I s F t s s ds                           (2.1) 
where: ( )a t is the cumulative number of cases of AIDS diagnosed by the year t  
 ( )I s  is the infection rate in year s, and 
( | )F t s  is the incubation period distribution among individuals infected in    
year s.  
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Brookmeyer (1996) gives a simple explanation for this equation: an individual, who 
has been infected in a previous year s, would have an incubation period shorter than t 
– s if that individual is diagnosed with AIDS in year t. The value of ( )a t can be 
obtained from national surveillance data on AIDS and ( )F t  can be derived from 
various epidemiological studies. These can then be used to obtain information about 
the incidence of new infection ( )I s . 
 
In using this method, it is assumed that: 
1. There is sufficient data available for accurate estimation 
2.  Incubation does not vary across populations (Bacchetti et al., 1993). 
 
Earlier works using back-projection include studies done by Bacchetti et al. (1993) 
and Brookmeyer (1996). 
 
Estimates from back-calculation are not reliable, and produce large statistical 
uncertainty due to limited information on the incubation period distribution and 
because the time of HIV infection is usually unknown (Kaplan and Brookmeyer, 
1999). In most African countries, there are no accurate data and statistics on the AIDS 
epidemic due to incomplete reporting of AIDS cases. For those countries with data on 
AIDS, there are errors in AIDS incidence data due to underreporting of AIDS cases, 
reporting delays, and non-response bias.  
 
Williams et al. (2001) note that methods of back-calculation have not been applied to 
South African data as reporting of AIDS cases is voluntary and the data are too 
inconsistent and incomplete to be of use. 
 
2.1.3 CROSS-SECTIONAL STUDIES 
 
A cross-sectional study is a study which examines the presence or absence of a 
disease and its exposure at a particular point in time. The respondents who take part in 
a cross-sectional study usually do not have previous knowledge of their disease or 
exposure. Although cross-sectional studies are flexible because they can either study 
whole populations, or a representative sample; they are prone to selection bias in 
choosing the respondents. Also, the characteristics of the population surveyed may 
11 
 
change with time due to deaths from the HIV virus. Despite these disadvantages 
however, cross-sectional studies are more cost effective and time saving than the 
cohort study. Because cross-sectional studies are more flexible in terms of cost and 
ease of implementation, most researchers have resorted to using the concept to 
propose different methods of estimating incidence. 
 
2.1.4 TRENDS IN HIV PREVALENCE 
 
Various statistical models have been developed to estimate incidence from cross-
sectional surveys. These estimates can be obtained by using trends in HIV prevalence 
obtained from serial cross-sectional surveys. Incidence is indirectly estimated by the 
slope of prevalence over time assuming the population remains constant over time. 
However, some other models have been described in literature (Brookmeyer et al., 
1995; Williams et al., 2001).  
 
Cleghorn et al. (1998) used one of these models to estimate HIV incidence in patients 
attending a Sexually Transmitted Disease clinic in Trinidad and Tobago between 1987 
and 1991. The annual incidence rates were calculated as the difference in prevalence 
at two time points divided by the time period between the two surveys. Although 
estimates obtained from serial cross-sectional surveys are less expensive to obtain, 
one major disadvantage is that there are high levels of non response. Also, the 
population surveyed could be changing because of unknown selection bias. (Cleghorn 
et al., 1998).  
 
In South Africa, Williams et al. (2001) presented a method of estimating the incidence 
of HIV infection by combining data from a single cross-sectional survey with 
information on the change in the overall prevalence with time. They state that while 
most models work under the assumption that prevalence is unchanging, this is not 
applicable to the South African scenario where the epidemic is still on the increase. 
To address this issue, the authors propose a model that links the prevalence of 
infection among women of age a at time t, to the incidence with assumptions about 
the growth rate of the epidemic and AIDS mortality rate. Their model was based on 
observed age-specific sero-prevalence data on 3,163 women, aged between 15 and 49 
years, attending antenatal clinics in a rural district in Kwazulu-Natal province. 
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They presented 2 methods of obtaining age-specific incidence from age-prevalence 
curves (Williams et al., 2001).  
 
In the first method, a smoothed prevalence curve, estimates of the AIDS related 
mortality and the current epidemic growth rate were used. The authors suggest using 
the slope of the age-prevalence curve = P a t P a t( , ) ( , )  1 1 , 
where P a t( , ) = Prevalence at age a at time t and  
P a t( , ) 1 1 = The prevalence at age a 1at time t 1 . 
Therefore to obtain incidence, the prevalence at any age a 1must be reduced by the 
amount by which the prevalence has increased and by the proportion of people who 
have died due to AIDS related diseases in the last year. The incidence at age a at time 
t; I a t( , ) ) is then given as: 
( 1)
( , ) ( , ) ( 1, )
( )
P t
I a t P a t P a t e
P t
    
Where P a t( , ) is the age-specific prevalence at age a at time t, ( )P t is the average 
adult prevalence at time t, and µ is the AIDS related mortality per year.  
 
Williams et al. (2001) also note that although this model is simple and easy to use, it 
assumes that the survivorship function of those with HIV infection is exponential and 
does not take into consideration the fact that infections in those of age a will have 
been accumulated over the years. 
 
In the second method, P a t( , ) is a function of the proportion of infected people; 
c a t( , ) , and the proportion of susceptible people of age a at time t; s a t( , ) .  
i.e.  
( , )
( , )
( , ) ( , )
c a t
P a t
c a t s a t

  
 
This proportion of people at risk s a t( , )  is the probability that a person who has 
reached age a remains uninfected by the virus. This method assumes any form for the 
survivorship function, and permits changes in prevalence over time. It however 
requires that the data be detailed in order to give correct estimates. 
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Using these models, the average annual incidence per susceptible persons in the 
population aged 15-49 was 11.4%, with a confidence interval of (10.0-13.1). The 
annual incidence of infection per susceptible increased from 5.4% (3.3–8.5%) at age 
15 years to 24.5% (20.6–29.1 %) at age 22 years and declined to 1.3% (0.5–2.9%) at 
age 50 years (Williams et al., 2001). 
 
Parekh and McDougal (2005) however, pointed out that although this approach was 
useful, the assumptions about the growth rate and mortality rate would have a 
significant impact on the outcome. 
 
2.1.5 LABORATORY METHODS 
 
It is important to note that none of the preceding methods above provide information 
on exactly when an individual became infected with HIV, and this is the most 
important consideration in measuring new occurrences or incidence. It has been 
suggested that dependence on cohort studies and estimates based on statistical models 
of AIDS cases and prevalence data can be eliminated if there was a reliable means of 
distinguishing individuals with recent infection within a population. (McDougal, 
Pilcher, Parekh, Gershy-Damet, Branson, Marsh and Wiktor, 2005). 
 
Some laboratory tests have recently been developed that detect new HIV infection in 
the time between HIV infection and detection of HIV antibodies. These test methods 
differentiate recent HIV infection from established infection and estimate incidence 
from cross-sectional surveys (Parekh and McDougal, 2005; McDougal et al., 2005). 
Incidence estimates are subsequently obtained by using the relationship between 
prevalence, incidence and the duration of the window period. 
 
One of such tests is the Serologic Testing Algorithm for Recent HIV Seroconversion 
(STARHS) test, detailed by Janssen, Satten, Stramer, Rawal, O‟Brien, Weiblen, 
Hecht, Jack, Cleghorn, Kahn, Chesney and Busch (1998). This test is also known as 
the „sensitive-less sensitive‟ test and it is a testing algorithm which involves testing a 
single blood specimen from a person with HIV infection using two separate ELISA 
tests, with one of the tests being more sensitive to antibodies than the other. In the 
study by Rutherford et al. (2000) for example, patients who are positive on the 
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sensitive test, and negative on the less sensitive test were estimated to have become 
infected within 129 days, with a 95% confidence interval of 109–149 days 
(Rutherford et al., 2000). The estimate of incidence was given as: 
 
365
100
n
I x x
N T
   
    
                             (2.2) 
where I is the incidence per year, 
n is the number of persons who were positive on the sensitive test and negative on the 
less sensitive test 
N is the sum of n and those who are HIV negative on both tests, 
T is the estimated number of days between seroconversion on both tests, given as 129 
days in the above study, which was based on ELISA testing. 
 
A study carried out by Gouws et al. (2002) in South Africa estimated the incidence of 
HIV using the STARHS data for women attending antenatal clinics in Hlabisa, 
Kwazulu-Natal. Blood serum was collected from 2623 women aged 15 to 50, and this 
was done anonymously. 
 
The authors also used the mathematical model developed by Williams et al. (2001) to 
compare estimates to those obtained from the STARHS method. The results were very 
similar-except for higher estimates of incidence in women aged 40 to 44 years using 
the STARHS method. They state that more research is required to confirm the 
accuracy of these results. 
 
Brookmeyer and Quinn (1995) also propose a method of estimating HIV incidence 
rates based on a single cross-sectional survey. In this approach, a group of individuals 
are tested for HIV antibodies. Those who test negative or indeterminate for HIV are 
tested again via the p24 antigen test, which recognizes early HIV infection better than 
the standard HIV antibody test. The expected proportion of p24 antigen positive is 
given as:  
    *p I                                       (2.3) 
where „I‟ is the incidence rate and μ is the mean duration of the p24 antigen 
seroconversion period. This estimated mean duration was given as 22.5 days with a 
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95% confidence interval of 13-42 days, based on a Markov model of transitions 
between states, fitted to their data. 
 
One source of uncertainty with this method is concerned with μ, the mean duration. 
Le Vu, Pillonel, Semaille, Bernillon, Le Strat, Meyer, and Desenclos (2008) explain 
that the number of days during which the p24 antigen is detectable is too short, and 
has even become shorter because of the development of new antibody tests that are 
more effective. Due to this uncertainty in the mean duration, incidence estimates 
obtained should be cautiously recommended. Another limitation with this method is 
that large sample sizes are required, especially in low incidence areas (Brookmeyer 
and Quinn, 1995). 
 
Few of these laboratory methods have been introduced in Africa, despite frequently 
being used in the more developed countries like the United States. 
 
2.2 ISSUES IN HIV TESTING 
 
Although current HIV antibody testing methods detect infections, they do not 
distinguish between recent (incident) and long-term (prevalent) infections (Parekh and 
McDougal, 2001).  Therefore, to accurately estimate an individual‟s status, it is 
important that the type of HIV test used is one that easily makes this distinction 
between what type of infection it is.  
 
Tests to diagnose HIV infection are of different types: those that detect antibodies, 
tests that identify antigens such as the p24 antigen test, tests that detect /monitor viral 
nucleic acids and those that provide an estimate of T lymphocyte numbers 
(Constantine, 2001). 
 
When choosing a test, considerations should be given to the cost of the test, its 
sensitivity and its specificity. The sensitivity of a test is the probability that a diseased 
person will be correctly classified by a test; while the specificity of a test is the 
probability that a non-diseased person will be correctly classified by a test (Litvak, 
Tu, and Pagano, 1994).  
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A perfect test has 100% specificity and 100% sensitivity but currently, there is no 
perfect HIV test. Studies have shown that the p24 test has a specificity of 99%, and a 
sensitivity of about 79%. Conversely, the HIV RNA test has a sensitivity of 100% but 
a specificity of 97%. The ELISA test has a sensitivity of 77% and specificity of 97% 
(Hecht, Busch, Rawal, Webb, Rosenberg, Swanson, Chesney, Anderson, Levy, and 
Kahn, 2002). As new tests evolve, the costs, sensitivity and specificity of the tests are 
constantly changing. The table below summarizes the details of the three tests from 
Hecht et al. (2002) and it is important to note that these numbers have changed over 
the years.  
 
Table 2.1: Sensitivity, specificity & cost of different HIV tests 
TEST SENSITIVITY SPECIFICITY COST 
p24 Antigen 79 99 $25 
HIV RNA 100 97 $119 
ELISA 77 97 $20 
  
Litvak et al. (1994) provided an overview of the relationship between sensitivity and 
specificity. If sensitivity is improved by retesting all negative samples, specificity will 
decrease; and if the specificity is improved by retesting all positive samples, 
sensitivity will decrease. Both approaches involve an increase in cost because either 
way, testing is duplicated. According to Litvak et al. (1994), the only way of 
increasing the quality of the test kits and reducing cost simultaneously is by pooling 
the samples together. 
 
2.3 POOLED TESTING 
 
In a standard HIV screening test, patients are tested one at a time. Patients who test 
positive are retested with a confirmatory test, while those who test negative are not 
retested. When estimating incidence, standard screening is not cost efficient because 
we have to test each individual. Various strategies have been developed recently to 
overcome this inefficiency in cost. One of these developments is the grouping of 
samples together and testing them as if they were one sample. This is known as 
pooling.  
 
Pooled testing is also known as group testing and this procedure was developed by 
Dorfman (1943). The method was first used in the United States to detect syphilis in 
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U.S soldiers going off to World War II. Under this program, a sample of blood was 
first drawn from each man, and each blood sample was then tested for the presence of 
the syphilis antigen. However, Dorfman (1943) proposed that instead of testing each 
individual sample, the blood samples should be pooled into a certain number of 
groups, and these groups would now be tested instead of the individual samples. If the 
pool tests negative, it means that none of the individual samples in that pool has the 
disease, hence, it will not be necessary to test the individual samples making up that 
pool. If the pool tests positive, the individuals making up the positive pool would be 
tested one by one to determine which particular ones are positive (Dorfman, 1943; 
Brookmeyer, 1999). A diagrammatic representation of the Dorfman pooling algorithm 
is given below in Figure 2.1.  
 
Chen and Swallow (1990) outlined the goals behind pooled testing which are mainly 
two-fold:  Firstly, to detect all individuals in the population as being infected with a 
particular disease or not, while reducing the number of tests at the same time. This is 
known as the “Classification problem”. The second goal is to estimate the proportion 
of individuals who have a particular disease in a population (prevalence), without 
identifying the infected individuals. In statistical literature, this is known as the 
“Estimation problem” (Kim, Hudgens, Dreyfuss, Westreich, and Pilcher, 2007). 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1: Diagram of dual stage pooling algorithm as proposed by Dorfman 
(1943). Individual blood sera pooled into groups of n and these groups are tested. 
The individuals making up the positive pools are retested to determine which 
particular individuals are positive. 
 
Total number (N) of individuals to be tested 
Grouped into pools of size n 
Positive Negative 
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The classification problem aims at reducing the expected number of tests involved in 
the grouping procedure, while the estimation problem aims to minimize the mean 
squared error of the proportion of positives for a fixed number of tests (Hung and 
Swallow, 2000).  
 
2.3.1 VARIANTS OF POOLING 
 
The original pooling algorithm as proposed by Dorfman (1943) is quite simple and 
has been used as a foundation for studies of infectious diseases. Kline, Brothers, 
Brookmeyer, Zeger and Quinn (1989) for instance undertook a study to determine the 
accuracy and cost effectiveness of estimating HIV sero-prevalence in a population 
survey using pooled testing. In their procedure small groups of at most 15 samples 
were created. If the test result is negative, all 15 samples are declared negative. If the 
test result is positive, then each of the 15 samples is tested individually. They 
observed a cost reduction of up to 80% as compared to individual testing of all 
samples. 
 
Some other pooling procedures have been proposed as an extension of the above 
pooling strategy. Litvak et al. (1994) discussed two different group testing methods in 
which positive groups are split into several subgroups of almost equal size, denoted as 
T2
 
and a subsequent extension as T2
+
.  For the first test (T2), if the pooled sample 
example above tests negative, then all 15 samples are declared negative. If it tests 
positive, then it is divided into 2 different subgroups of size 7 and size 8. The testing 
procedure is then repeated within each of the subgroups. For the second test (T2
+
), if 
the pooled sample tests negative, it is retested.  
Each group that produces a negative outcome is retested at most r-1 times (where r is 
the maximum number of times a group will be retested before being classified or split 
further into smaller groups). If all r-1 tests are negative, the group is classified as 
negative; otherwise, it is classified as positive. They concluded that both methods 
were better than Dorfman‟s procedure.  
 
Johnson and Gastwirth (2000) describe a two stage procedure which is similar to 
Dorfman‟s algorithm. In the first stage every individual is randomly pooled into 
groups of size k≥1. Due to the fact that some errors may occur in this stage, a second 
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stage is adopted. In the second stage, a random sample of units from the pools/groups 
that tested negative in the first stage are pooled into new pools and are retested. If a 
pool or group tests positive in the second stage, then all the individual samples that 
make up that pool are tested by a gold standard test to identify the samples with the 
specific characteristic in question. The idea behind re-pooling a portion of individuals 
from negative pools is that accurate inferences can be made about the accuracies of 
the test used; and the probability of having a false negative result pass through the 
system is limited. 
 
A simple extension of Dorfman‟s procedure is known as Hierarchical group testing or 
multistage testing.  In this method, a master pool (n) comprising all samples is first 
tested. If the result is positive, the pool is then divided into non-overlapping sub-
pools. As the name implies, the re-grouping of such samples can be divided into as 
many stages as possible, until individual samples are tested (Kim et al., 2007).  
Brookmeyer (1999: 609) describes the procedure for the single stage pooling as 
follows: 
“N randomly selected individuals are allocated to one of 1n  pools that each consist of  
1c  individuals.  Suppose 1r  of the n1 pools test positive (i.e., at least one of the 
individuals in each of these pools has the disease) and 1s  of the pools test negative 
(i.e., all individuals in each of these pool (sic) do not have disease), where 
1
r + 1s = 1n . 
The likelihood function is given as: 
 
                                    (2.4)   
 
The maximum likelihood estimator of the overall prevalence p (Thomson, 1962) is: 
                 pˆ = 1
1
11/
1
c
n
s 
 
 
  ”                                                               (2.5)    
Brookmeyer (1999: 609) further states that: 
“In a multistage pooling study, the positive pools identified at each stage are 
subdivided and tested.”  
 
   11
1
1
1 1 1(1 ) 1 (1 )L
rc s cn
p p
r
   
 
 
 
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“For example, in stage 2, each of the 
1
r  positive pools identified at stage 1 is divided 
into pools consisting of 2c  individuals. Suppose the jth positive pool from stage 1 
yields 2 jr  positive and 2 js  negative pools in stage 2 (j=1, …, 1r ). The 2 jr  positive 
pools are then subdivided and tested in stage 3.  More generally, at the ith stage, 
pools of size ic are constructed from the positive pools identified at stage i-1.  The 
numbers of positive and negative pools that originate from the jth positive pool of 
stage i-1 are called ijr  and ijs  respectively. The total number of positive pools at 
stage i is: 1
1i ij
i
j
r
rr 

  (for i≥2) and the total number of negative pools at stage i 
is 1
1 ij
i
j
r
i ss


 .  The total number of stages is called k. 
 
The likelihood function of the general multistage pooling study can be expressed as a 
product of conditional probabilities of the pooling results from stage i given the 
results from stage i – 1.  At stage i, the conditional probability of observing ijr  
positive pools and ijs  negative pools originating from the jth positive pool at stage i-
1, conditional on the event that at least one of the ci-1 individuals from this pool has 
the disease is: 
     
ijij iij ij i
ij 
rs  cc
1
r  + s
1 1 1
   r  
1 (1 )
ij
i
c
p p
p
L


 
 
 
  
 
.                                                           (2.6)  
The likelihood function for k stages is: 
-1
1 ij
2 1
* L
irk
i j
L L
 
  ”                                                      (2.7)    
Substituting for ijL  “and simplifying, we obtain:  
L      1 1 11 k
krN c
pp                                            (2.8) 
where 
1 1 i i
k
i
N c s

  is simply the total number of individuals in negative pools, 
k
r is the final number of positive pools identified at kth stage and kc is the number of 
individuals in each of these positive pools.” (Brookmeyer, 1999: 609). 
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“Each individual in the negative pool contributes the factor  1 p  and each positive 
pool contributes the factor   1 1 k kc
r
p  .  The likelihood depends only on the final 
size of the positive pools, ck, and not on the pool sizes at earlier stages (ci, i<k). After 
setting log L
p


=0, we obtain  
1
1
1ˆ
kcN
N
p 
   
 
 .” (Brookmeyer, 1999: 609-10).                          (2.9) 
 
Brookmeyer (1999) explains that if there is an assay to detect early onset of the 
disease, we can estimate incidence from a multistage pooling study by substituting pˆ  
for p   in the incidence equation: p  = *I  . Thus an estimate of incidence Iˆ  is given 
as: 
1
11
1ˆ
kcN
N
I

 
  
  
  
 
 .                                                 (2.10) 
 
A practical example of multistage pooling is outlined in the NC STAT program by 
Pilcher, McPherson, Leone, Smurzynski, Owen-O'Dowd, Peace-Brewer, Harris, 
Hicks, Eron, and Fiscus, (2002) using a three stage hierarchical algorithm as follows: 
First, disjoint master pools of 90 specimens are tested. Second, positive master pools 
are divided into sub pools of 10 specimens each and these sub pools are tested. Third, 
specimens from the positive sub pools are individually tested. 
 
Multistage testing has been used in the detection of acute HIV infection (Pilcher, 
Price, Hoffman, Galvin, Martinson, Kazembe, Eron, Miller, Fiscus, and Cohen, 2004; 
Pilcher, Fiscus, Nguyen, Foust, Wolf, Williams, Ashby, O'Dowd, McPherson, Stalzer, 
Hightow, Miller, Eron, and Cohen, 2005; Quinn, Brookmeyer, Kline, Shepherd, 
Paranjape, Mehendale, Gadkari, and Bollinger, 2000; Brookmeyer, 1999) and will be 
the focus of this research report. 
 
Johnson, Kotz, and Wu (1991) examined hierarchical algorithms in the presence of 
test errors. They derived the expected number of tests, pooling sensitivity and pooling 
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specificity for a hierarchical algorithm. They also allow sensitivity and specificity to 
be dependent on the number of pools in each stage. 
 
An alternative to Hierarchical group testing is a method called array based specimen 
pooling. Kim et al. (2007) note that this approach is frequently employed in genetics 
but remains underutilized in the infectious disease setting. To begin with, n
2 
specimens are usually arranged in an n x n matrix format, and pools of size n are 
created from all samples in the same row or in the same column. Using the 
assumption that there are no false negatives, the pools are tested, and all positive 
specimens will lie at the intersection of a positive row and a positive column pool. 
Kim et al. (2007) note that this method is not effective for estimating infectious 
diseases mainly because it requires an extremely large number of specimens, and it 
does not consider test errors i.e. false negatives and false positives. It should be noted 
that this variant is mentioned for the sake of completeness, but not used in the study. 
 
2.3.2 ASSUMPTIONS IN POOLING 
 
The feasibility of pooling blood samples have been studied by various authors such as 
Quinn et al. (2000), and Brookmeyer (1999). Sergeant and Toribio (2004) report that 
pooled testing is based on a number of assumptions: 
1. The status of an individual is independent of the status of others both 
within and outside the pool. 
2. The test used is sensitive and specific enough to detect when one of the 
pooled samples is positive or negative. 
3. The sensitivity of the test for a pool is approximately the same as it is for 
an individual sample. (Litvak et al., 1994). 
4. The dilution of individual samples into the group does not affect the 
accuracy of the tests. 
 
2.3.3 THE DILUTION EFFECT 
 
Gupta and Malina (1999) define the dilution effect as the failure of tests to detect an 
infected sample when it is diluted with a large number of negative samples. Zenios 
and Wein (1998) note that if the size of a pool is large, some of the positive sera may 
be excessively diluted by negative sera and consequently become undetectable in the 
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pool. This can compromise the sensitivity of a test thereby resulting in the 
underestimation of prevalence and may also lead to a loss of accuracy. 
 
To examine the effect of dilution, Wein and Zenios (1996) develop a hierarchical 
statistical model which links the HIV test output with the antibody concentration in 
the pool, thus capturing the effect of pooling different samples together. Their 
approach simultaneously captures the dilution effect, while estimating prevalence 
directly from optical density (the attribute that is observed and measured in an ELISA 
test) readings. They assumed that the optical density of the pool is the average of the 
optical densities of the individual samples. Their results show that although the 
dilution effect may lead to a slight loss of accuracy during pooled testing; this can be 
overcome by the choice of the pool/group size. In spite of this concept, the analysis 
has one main disadvantage- consideration is not given to the effect of the window 
period donors in the model. 
 
2.3.4 OPTIMAL POOL SIZE 
 
One advantage of pooled testing is the reduction of the number of tests used, and the 
subsequent reduction in the cost of testing. The optimal pool size is the one that 
provides accurate results whilst minimizing the loss in sensitivity and specificity of 
the tests. In dual group and multistage testing, the optimum choice of the size of pools 
depends on the prevalence of the disease in the population, and the accuracy and cost 
of the tests used (Johnson and Gastwirth, 2000). Generally, group sizes are 
predetermined by the laboratory personnel in charge of the procedure. 
 
2.3.5 CONFIDENCE INTERVALS 
 
Measures of the uncertainty due to random error are typically presented in 
epidemiologic research in the form of a confidence interval (Cole, Chu and 
Brookmeyer, 2006). Kline et al. (1989) conducted a study to evaluate the feasibility 
and accuracy of pooled samples in estimating HIV prevalence in large samples. Point 
and interval confidence estimates were obtained from the pooled sera. In their study, 
blood samples from two large population surveys were pooled separately. Prevalence 
was estimated by maximum likelihood and given as:  
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1
1 (1 [ / ])ˆ cs np                                      (2.11) 
and the asymptotic variance of  pˆ  is estimated as : 
[2/ ] 1
2
{ / [1 ( / )] cs n s n
v
c n

                                    (2.12) 
where n represents the number of groups/pools, c  is the number of blood samples 
making up n  and s  is the total number of positive pools. 
 
Generally the approximate 95% confidence interval was given by Kline et al. (1989) 
as:  
     ˆ 2p v                                               (2.13) 
The confidence intervals to be used and compared in this report are based on what has 
been used in similar literature (Cowling, Gardner, and Wesley, 1999; McDougal et 
al., 2005; Hauck, 1991 and Brookmeyer et al, 1995). The confidence intervals are 
defined as:  
Normal Approximation Method of the Binomial Confidence Interval:  
1 / 2
(1 )p p
p z
n


                                      (2.14) 
where p = proportion of interest and n = sample size. 
Exact Binomial Confidence Interval:  
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where m is the number of pools and x is the number of positive samples 
detected. 
Exact Poisson Confidence Interval:  
Upper limit:  2
1
/ 2;2 2
2
x                (2.17) 
Lower limit:  2
1
1 / 2;2
2
x               (2.18) 
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where x is the observed count and  2 ;P a is the Pth quantile of the chi-
square distribution with a degrees of freedom. 
Another confidence interval defined in McDougal et al., 2005 is given as:  
ˆ 1.96
I
p
N
                  (2.19) 
where pˆ is the proportion of interest, „I‟ is the annualized incidence rate, and N is the 
number of infected individuals classified as positive on the assay or test used 
(McDougal et al., 2005). This will be termed the McDougal approach confidence 
interval. 
 
Cowling et al. (1999) note that in low prevalence populations, the lower confidence 
limit may be negative due to the “inappropriateness of the large-sample normal theory 
in extreme-low-prevalence situations”. To resolve this problem, Hauck (1991) 
proposed an alternative confidence interval that will not give values less than zero, 
and does not depend on the asymptotic variance ( v ). The two methods recommended 
were: 1) to obtain an asymmetric interval that uses the normal approximation with a 
continuity correction and 2) to obtain exact confidence intervals by assuming a 
binomial distribution for the number of positive pools (Hauck, 1991). Due to the high 
prevalence of HIV in South Africa, it is safe to assume that we are unlikely to obtain a 
negative confidence limit; therefore, the method of Kline et al. (1989) is used to 
obtain the confidence intervals in this report. 
 
2.3.6 OTHER AREAS OF APPLICATION 
 
Pooled testing has been successfully used to screen blood donors in less-developed 
countries for the HIV virus (Emmanuel, Bassett, Smith, and Jacobs, 1988). However, 
the validity of this has been questioned because of the possible loss in sensitivity 
during this process (Johnson and Gastwirth, 2000; Kennedy, 2004a). 
 
Pooling has been applied to the study of other infectious diseases such as Hepatitis B, 
Hepatitis C, and West Nile Virus (Westreich, Hudgens, Fiscus and Pilcher, 2008). The 
extension of this method into the study of HIV has also proved useful especially in the 
area of reducing the costs of HIV tests (Litvak et al., 1994; Saraniti, 2006; Kline et 
al., 1989). Chen and Swallow (1990) pointed out that it is used to quantify resistance 
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factors in plants. It has also been used to estimate disease prevalence in animals and 
infection rates in insect vectors (Sergeant and Toribio, 2004; Munoz-Zanzi, Johnson, 
Thurmond, and Hietala, 2000; Maherchandani, Munoz-Zanzi, Patnayak, Malik, and 
Goyal, 2004). Other applications are in the area of genetics and the demonstration of 
cost efficiency and reduction in pharmaceutical companies (Westreich et al., 2008; 
Xie, Tatsuoka, Sacks, and Young, 2001). 
 
Kennedy (2004b) notes that in populations with low prevalence rates, pooling can 
result in more accurate tests. Although it is a cost reducing method, cost savings are 
only going to be substantial where there are a large number of samples. 
 
In summary, the various methods of estimating incidence have been examined. 
Although all the methods outlined above have their disadvantages, they are still in use 
in different countries all over the world today. Pooled testing provides a way to group 
samples together, test them, and still be able to estimate prevalence and incidence 
from these samples-except of course, at a lower cost. One issue that has not been 
addressed in the literature is the sensitivity of incidence estimates to the different 
assumptions in pooling and this will be discussed in upcoming chapters. 
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CHAPTER 3 : METHODOLOGY 
 
3.1 STUDY POPULATION 
 
The sample that initiated this study was made up of consenting attendees at the 
Hillbrow Esselen Street clinic in Johannesburg. This clinic is a primary care facility, 
providing HIV testing services, Sexually Transmitted Infections (STI) services, and 
Voluntary Counselling and Testing (VCT).  The respondents were recruited into the 
study between April and October 2004. Data was collected for each individual on age, 
sex, and the arm of the clinic where the test took place: either the STI or the VCT 
arm. No physical examination or behavioural data were collected in this survey. A 
total number of 1906 individuals were anonymously tested, of which 970 (50.9%) 
were male and 936 (49.1%) were female. The study was performed on anonymous 
and unlinked samples as specified by the ethics committee of the University of the 
Witwatersrand (Stevens, Akkers, Myers, Motloung, Pilcher and Venter, 2005). 
 
3.2 THE POOLING ALGORITHM (ESSELEN CLINIC DATA) 
 
From the 1223 respondents who tested negative on the ELISA test, a portion of the 
blood samples taken from each respondent was then used to create 12 pools of 100 
samples. This was done specifically to have an equal number of specimens in each 
pool. The balance of the samples (23) was later pooled, with negative results. 
 
Applying the RNA test on these 12 pools, 3 pools were found to be positive, 
indicating that there were positive individual samples within the pools; and 9 pools 
were negative-no further testing was required on these 9 pools. Therefore 300 samples 
would have to be retested. The 3 positive pools were split into 6 pools of 50. After 
testing, 3 of the 6 pools were found positive and 3 pools were negative. Thus 150 
samples were retested, while the other 150 needed no further testing. The 150 positive 
samples were again grouped into 15 pools of 10 from which 7 pools were found 
positive, and 8 pools were found negative. The 70 samples were then tested 
individually, and 8 of these were positive. The remaining 80 samples were negative, 
and needed no further testing.  
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Of the 23 other samples 2 pools of 10 were created, which tested negative on the RNA 
test. The remaining 3 samples were tested individually and also tested negative on the 
RNA test. 
 
3.3 POOLING STRATEGIES 
 
Two main algorithms are considered:  The first is based on Dorfman‟s (1943) dual 
stage approach where a number of samples are combined into pools of a certain size. 
If the pooled samples produce a value equal to or greater than the lower limit of 
interest for the pool then all individual samples in the affected pools are tested in the 
second stage. If the sample values are below the lower limit of interest, they are 
considered negative and no further tests would be performed on these pools. 
 
The second algorithm follows the example of a pooling strategy set by Quinn et al. 
(2000). The strategy is a 3- stage Hierarchical pooling algorithm with the following 
general structure:  
a) Firstly, a “Master Pool” containing all blood samples is tested. 
b) If the master pool is positive, we group samples into non-overlapping sub-
pools and test these sub-pools.  
c) Individual specimens from the positive sub-pools are tested. 
 
The pooling algorithm describing the method used is found below and is a 
modification of the algorithm used by Quinn et al. (2000). 
 
3.4 OTHER MODEL ASSUMPTIONS 
 
 The outcome of both the antibody test and the HIV RNA test is either positive 
or negative: there are no indeterminate results. 
 There are no errors in testing.  
 Constant sensitivity and specificity which is independent of pool size.  
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Figure 3.1: Pooling Strategy used in HIV testing for 1200 antibody negative 
respondents attending the Esselen Clinic in Johannesburg, South Africa. The 
results for the remaining 23 samples have been omitted in this figure. 
 
3.5 OPERATING CHARACTERISTICS OF POOLING 
ALGORITHMS 
 
The operating characteristics of pooled algorithms have been defined in group testing 
literature (Kim et al, 2007 and Westreich et al, 2008).  Denoting the dual stage 
algorithm defined by Dorfman (1943) by S2 and the three stage algorithm defined by 
Quinn et al. (2000) by S3, the characteristics of the algorithms are:  
 
 
Pooling &Testing 
12 test pools of 
100 
(12 x100) = 1200 
3 pools positive 
(3x100) = 300 
7 pools positive 
(7 x 10) = 70 
3 pools positive 
(3 x 50) = 150 
6 test pools of 50 
(6 x 50) = 300 
15 test pools of 10 
(15 x 10) = 150 
70 specimens tested 
individually 
No further testing 
9 pools negative 
(9 x 100) = 900 
3 pools negative 
(3 x 50) = 150 
8 pools negative 
(8 x 10) = 80 
No further testing for 
estimating incidence 
8 specimens 
positive 
80 specimens 
negative 
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Efficiency: The efficiency of a pooling algorithm is the expected number of tests per 
specimen required to identify all positive specimens (Kim et al, 2007). The efficiency 
of individual testing is 1, and an efficiency of less than 1 indicates that the pooling 
algorithm will require fewer tests on average than individual testing. Dorfman (1943: 
438) states that “the extent of the savings attainable by the use of the group method 
depends on the group size and the prevalence rate”. 
 
The efficiencies of the above algorithms are given as: 
E (S2) = 
1
(1 )nq
n
 
                                                   (3.1) 
E (S3) = 
11
1
n
n
n
q
q
n


 
                                                                                   (3.2) 
Where n  =pool size 
 q = 1- p  
 p =Prevalence 
 
Pooling Specificity ( )pS A : This is defined as the probability that an individual is 
categorized as negative by a particular pooling algorithm (A) given that the individual 
is truly negative. 
 
Pooling Sensitivity ( )eS A : The probability that an individual is categorized as positive 
by a particular pooling algorithm (A), given that the individual is truly positive. 
 
Positive Predictive Value (PPV): The probability that an individual is truly positive 
given that s(he) is categorized as positive by A and is given as:  
PPV =
( )
(1 ){1 ( )} ( )
e
p e
pS A
p S A pS A  
                          (3.3)
 
 
Negative Predictive Value (NPV): The probability an individual is truly negative 
given that s(he) is categorized as negative by A and is given as 
NPV = 
(1 ) ( )
(1 ) ( ) {1 ( )}
p
p e
p S A
p S A p S A

  
                             (3.4) 
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3.6 SIMULATION 
 
Incidence estimation will be further investigated using a simulation study, which 
examines the effects of pooling on different algorithms. The laboratory results 
obtained from the Esselen Street data were analysed and will be integrated into a 
simulation model aimed at evaluating the efficiency of two main pooling algorithms: 
The Dorfman (1943) 2-stage procedure and the Quinn et al. (2000) 3-stage pooling 
procedure. It should be noted that one can go beyond 3 stages in multistage pooling; 
however, most of the literature on this subject is limited to three stages.  
Firstly, a dataset with N subjects is generated to mimic a scenario where the true 
prevalence is p. This is done by simulating each subject‟s initial infection probability 
using a random number from a uniform distribution U [0, 1]. If the simulated 
infection probability is less than the selected prevalence level, the data point is 
labelled as positive and if it‟s greater than or equal to the selected prevalence level, it 
is labelled as negative. This typically corresponds to the 1
st
 test in which negative 
samples have antibody values below 500copies/ml and positive samples have 
antibody values equal to and greater than  500copies/ml. 
At this stage, each observation is classified as ELISA positive or ELISA negative. For 
each ELISA negative value, the „new infection‟ status is set by generating another 
uniform [0, 1] number, and classifying the observation as an old infection if this is 
>=specified annual incidence level (incidence * 18/52), otherwise it is classified as a 
new infection. The factor 18/52 is used to annualize the incidence estimate based on 
the window period estimate given by Janssen et al. (1998): 129 days (18 weeks) 
which is the mean time of seroconversion between the sensitive and the non-sensitive 
tests divided by 365 days (52 weeks), which is the number of days in a year. The 
RNA value for the observation is then generated. 
Because the Esselen Street study employed the use of HIV RNA test as the 2
nd
 assay, 
the characteristics of the RNA test were used for detecting recent infections in the 
simulated samples. Previous studies (Le Corfec, Le Pont, Tuckwell, Rouzioux, and 
Costagliola, 1999) indicate that threshold assay value used to identify positive 
samples based on the HIV RNA test is 750,000 copies per ml, with a value less than 
or equal to 400 being classified as RNA undetectable, and all other values are 
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classified as negative. The RNA values follow a log normal distribution (Wein and 
Zeinos, 1998). In order to take viral load into account, the values are generated as a 
mixture of normal distributions as follows: 
 For new infections: exp{N (0, 1)*0.1+log (10000} i.e. exp {N (4, 0.1)} 
 For old infections, another U [0, 1] number is generated. 
o If this is less than 0.5, the RNA value is generated from exp {N (0, 
1)*0.1+log (100000} i.e. exp {N (5, 1)}.  
o Otherwise it is generated as exp {N (0, 1)*0.1+log (1000000} i.e. exp {N 
(6, 0.05)}. 
 
Viral load values were not available for the Esselen Street clinic data and very few 
South African studies report mean RNA values. A study done by Shisana, Rehle, 
Simbayi, Parker, Zuma, Bhana, Connolly, Jooste and Pillay (2005) gives the median 
HIV RNA viral load as 3.9. In order to have infected individuals with varied viral load 
values, a mixture of distributions was used and a mean HIV RNA range of 4-6 was 
considered. 
 
The simulated samples are divided into predetermined pools of size k to imitate the 
random allocation of samples to pools in an actual laboratory testing. For each group 
of negative samples, 2 pooling algorithms are examined:  
a) Dual or 2-stage pooling: This is based on the Dorfman (1943) algorithm where 
the negative samples are combined into one pool. Here, pool samples with a 
value less than the set threshold will be considered as negative for HIV and no 
further grouping or testing will be performed. Otherwise, all the samples in 
that pool would be tested individually because it shows that there is at least 
one positive sample in that pool. 
b) Multistage (3 stage pooling).: This follows the same structure as the Dorfman 
algorithm, except that we further re-pool positive samples and only test 
individually in the third and final stage. 
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PARAMETERS:  
 
To set up the simulation described above, the general parameters required are: 
-  p =Prevalence: Prevalence is set between 25%-35% following the current 
HIV prevalence rates in South Africa (Welz, Hosegood, Jaffarc, Batzing-
Feigenbaum, Herbst and Newell, 2007). 
- I = Incidence range: The results from the Hillbrow study by Stevens et al. 
(2005) suggest that incidence is 12.9% (95% CI, 11.01%-14.8%). The range 
for incidence in the model will be set between 12% -15% as recommended by 
Beyrer et al (1996). 
-  =Mean duration of the RNA test before seroconversion. Quinn et al. (2000) 
estimates the period of HIV antigen positivity before seroconversion to be 
either 22.5 days (for the p24 test) or 28 days (for the HIV RNA test). The 
values of the window period used in the simulation will vary around these two 
figures. 
- Pool sizes: Pools of size 1 (all samples), 5, 10, 25, 50, 100 and 1000 are 
selected arbitrarily for the ease of analysis. 
 
A number of combinations are possible from the parameter set above but only a 
selected number of scenarios will be evaluated in Chapter 4. Estimates of the 
incidence rate, confidence intervals and number of tests needed are obtained for each 
of generated data sets and pooling scenario. For a given prevalence range, the relative 
efficiency and accuracy of both pooling strategies are examined and compared to 
individual testing. Discussions on the findings are presented in Chapter 4. 
 
3.7 STUDY LIMITATIONS 
 
The result of the data from the Esselen Street clinic is available for the direct 
estimation of incidence. However in order to discuss other characteristics of pooling 
algorithms, a simulation study is required to examine the theoretical aspects of this 
procedure. The method of choosing the sizes of pools is one of the limitations of this 
study - pooled sizes have been chosen depending on which sizes would make sub-
pooling easier. A major assumption of the setup is that there is no error in testing at 
any of the stages. The study also does not assess the sensitivity to the assumption of 
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no dilution effect, or the cost thereof. This is because the pool size chosen by the lab 
experts is assumed to take account of this. 
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CHAPTER 4 : DATA ANALYSIS AND RESULTS 
 
This chapter evaluates and discusses the results and examines issues around the 
different pooling algorithms, size and cost. The issues of optimal pool sizes and cost 
saving are also explored. All computations were done using SAS version 9.1 (SAS® 
Institute Inc., Cary NC, USA). 
 
4.1 SUMMARY RESULTS FROM ESSELEN STREET DATA 
 
The main objective of study conducted at the Esselen street clinic was to determine 
the prevalence of acute primary HIV infection among South African men and women 
attending a primary care clinic. The study further generates an estimate of HIV 
incidence based on a multistage pooling method.  
 
Despite the laboratory testing which was carried out, data made available from the 
study only contained summary level information which included demographic 
frequencies of the respondents, and pooled results.  Individual results of the antibody 
tests were not included. The summary of the demographic and test characteristics of 
patients attending the Esselen Clinic in Hillbrow are given in Table 4.1 below:  
 
Table 4.1: Frequency table of respondents attending the Esselen Clinic. A weakly 
reactive result means that the antibody test results were equivocal or 
indeterminate and needed confirmatory testing. 
  Male Female Total 
Negative 670 553 1223 
Weakly Reactive 5 6 11 
Positive 295 377 672 
Total 970 936 1906 
 
Of the 1906 individuals tested at the Esselen Street Clinic, 672 respondents were HIV 
antibody positive using the ELISA test and 11 were antibody equivocal or 
indeterminate. A total of 4 out of the 11 antibody indeterminate respondents tested 
positive for HIV RNA.  As it was not clear whether these 11 specimens had been re-
tested using the ELISA test before they were tested using the RNA test, they were 
discarded for the purposes of the simulation study.  
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The 1,223 respondents who were antibody negative were then tested with HIV RNA 
to detect acute infections using the pooling algorithm described in Figure 3.1. The 
results show that 8 respondents tested positive for HIV RNA. The prevalence of acute 
HIV infection in the overall study population was then calculated as 
12
1223
 or 0.98%. 
This is consistent with findings from a previous study by Kamanga, Thumbi, 
Nkhoma, Manamela, Bogoshi, Latka, Martinson, Karim, Kumwenda, Rees, 
Churchyard, McCauley, Gay and Cohen (2008). In their study, 6674 people attending 
two Sexually Transmitted Diseases (STD) clinics in Malawi and one research facility 
in South Africa were screened for HIV, with an overall prevalence of 1.2%. 
 
Based on the multistage pooling method, incidence is then estimated using the 
relationship between prevalence and the test window period as described in equation 
(2.2):  
 
12 365
100
1223 28
I x x
   
    
   
 
Therefore, the estimate of acute HIV incidence of the Esselen Street data is given as: 
12.79% (95% CI, 11.01%-14.8%).   
 
The major limitation of the data provided was the lack of adequate pooling 
information. However, the data was useful for investigating the sensitivity of the final 
conclusion to the assumptions. As a result, the simulation steps introduced in Chapter 
3.6 were performed and results are discussed in the following sections. 
 
4.2 SIMULATION RESULTS 
 
The subsequent sections show and discuss the direct estimates of incidence obtained 
from the different methods discussed in preceding chapters. 
The first approach examines incidence estimates derived from a single cross-sectional 
survey using the relationship between prevalence and the estimated window period: 
*p I  . Therefore calculations of incidence=
p
I

  per day. 
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Table 4.2: Estimated incidence rates (% per year) as a function of p, the expected 
proportion of positives, and mean duration µ ranging from 15 days to 40 days 
Prevalence Window period 
(p) 15 22.5 28 30 40 
0.1          2.4           1.6           1.3           1.2           0.9  
0.12          2.9           1.9           1.6           1.5           1.1  
0.15          3.7           2.4           2.0           1.8           1.4  
0.2          4.9           3.2           2.6           2.4           1.8  
0.25          6.1           4.1           3.3           3.0           2.3  
0.3          7.3           4.9           3.9           3.7           2.7  
0.35          8.5           5.7           4.6           4.3           3.2  
0.4          9.7           6.5           5.2           4.9           3.7  
 
For a given set of values of prevalence (proportion of positives), Table 4.2 shows the 
incidence rates that would be estimated from a cross-sectional survey and shows the 
sensitivity of these rates to the different assumptions about the mean duration (  ). 
 
As indicated in equation (2.5), incidence rates are inversely proportional to the mean 
duration of the assumed test. When prevalence is given at 30% with a 40 day mean 
duration of an assumed test, incidence is estimated to be 2.7%.  A window period of 
28 days with a given prevalence of 15% results in a lower estimate of 2%. 
  
Brookmeyer and Quinn (1995) state that disadvantages of this method are that large 
sample sizes are required; and there are uncertainties associated with the estimation of 
the mean duration or window period. For the purpose of this study, a mean duration of 
28 days is used throughout the analysis as suggested in the literature (Le Corfec et al, 
1999). 
 
Measures of uncertainty in epidemiologic research are typically obtained by 
computing confidence intervals for calculated estimates (Cole et al, 2006). Table 4.3 
below presents the various confidence intervals for individual-incidence estimates 
based on the confidence intervals defined in equations (2.14) to (2.17). 
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Table 4.3: Confidence intervals of incidence estimates with varying prevalence 
and sample size and  =28 days 
  N=1000 N=2000 N=5000 
  p=25% p=30% p=35% p=25% p=30% p=35% p=25% p=30% p=35% 
Incidence 
          
19.40  
          
30.49  
          
40.48  
          
21.17  
          
26.09  
          
34.56  
         
17.60  
         
22.95  
         
31.22  
Confidence 
Intervals:  
                  
„McDougal 
Approach‟  
18.53-
20.28 
29.36-
31.63 
39.14-
41.82 
20.52-
21.81 
25.36-
26.82 
33.7-
35.43 
17.23-
17.97 
22.52-
23.38 
30.69-
31.74 
Normal 
Approximation 
8.02-
30.78 
15.73-
45.26 
23.02-
57.95 
12.77-
29.57 
16.52-
35.66 
23.27-
45.86 
12.8-
22.39 
17.34-
28.57 
24.42-
38.02 
Exact Binomial 
9.72-
34.51 
17.5-
49.16 
24.86-
61.99 
13.6-
31.37 
17.39-
37.54 
24.16-
47.82 
13.12-
23.09 
17.67-
29.29 
24.77-
38.79 
Poisson  
9.69-
34.72 
17.43-
49.52 
24.73-
62.52 
13.56-
31.5 
17.34-
37.71 
24.08-
48.07 
13.1-
23.14 
17.64-
29.37 
24.71-
38.9 
 
Using the simulation procedure described in Chapter 3.6, data points are generated 
from a uniform distribution, U (0, 1) with the parameter p ranging from 25% to 35% 
and sample size ranging from 1,000 to 5,000. When prevalence (p) is set to 25%, and 
the sample size is set to 1,000, the first simulation results indicate that 261 samples 
are ELISA positive while 739 are positive. From these negative results, 11 individual 
samples were positive for HIV RNA thus giving a direct incidence estimate of 19.4% 
(Kline et al, 1989, CI: 18.53-20.28). The normal approximation gives a wider interval 
of (CI: 8.02-30.78), however the Binomial and Poisson intervals are very similar (CI: 
9.72-34.51; 9.69-34.72). This similarity between the latter intervals is acknowledged 
and discussed by Lehmann (1999), for cases where n is large (n> 30). When 
prevalence is assumed to be 35% in N=2000 samples, the incidence is calculated to be 
34.56% (CI: 33.7%-35.43%) using the McDougal approach as given in equation 
(2.17); and a wider interval of 23.27%-45.86% using the normal approximation 
approach. Results from Table 4.3 above show that there are similarities in the results 
of the confidence intervals obtained from the Binomial and Poisson approach.  
 
Although the McDougal approach to the confidence intervals yields the shortest 
confidence interval; Cowling et al, (1999) note that these confidence intervals provide 
poor coverage of the limits and can sometimes give a misleading confidence in the 
estimate. Hauck (1991) suggests that confidence intervals should be based on exact 
binomial probability calculations instead. 
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4.3 POOLING RESULTS 
 
For the pooling section of the study, samples were generated according to the 
simulation process in Chapter 3.6. For each generated sample, incidence is calculated 
using 2 main pooling algorithms:  
1. Dual (2) stage pooling 
2. Multistage (3 stage pooling). 
Incidence estimates for groups of 1 means that all samples are tested individually, and 
this is taken to be our “single stage” pooling; results from which will be compared to 
the 2 and 3-stage algorithms. 
 
4.4 DUAL STAGE ALGORITHM (2-STAGE POOLING): 
 
A 2 stage algorithm is introduced to examine the efficiency of pooling on incidence 
estimates and to compare the confidence intervals from this scenario to the individual 
level (single stage) procedure. 
 
For each sample size generated, a 2 stage pooling scheme is applied to that set. Two 
broad set-ups are considered, with prevalence varying from 25%-35%, while setting 
the true incidence to be 15% and 12 % respectively. 
 
4.4.1 ASSUMING INCIDENCE OF 0.15 
 
Table 4.4 shows the calculated estimates of incidence, its confidence interval and the 
number of tests required for 3 different sample sizes: N=1,000; N=2,000 and 
N=5,000. 
 
Considering Table 4.4: With an assumed prevalence of 25% and a sample size of 
1,000; incidence is calculated as the number of new infections divided by the number 
of antibody negative individuals. The antibody negative samples were obtained from 
our simulation as: number of antibody positive samples (258) subtracted from total 
number of samples (1000) which gives us 742 negatives. These 742 samples are then 
grouped into 7 pools of 100, with the 8
th
 pool containing only 42 samples; as 
stipulated in the simulation procedure. The number of tests required at this stage is 8, 
since this is the number of pools available. Only one pool of 100 was found to be 
negative, thus 7 pools had to be tested individually to identify how many samples 
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were positive. 6 pools containing 100 (600) were tested individually, with 1 
incomplete pool of 42. Therefore, the total amount of tests required for this simulation 
was 8+600+42; which gives 650 tests in total. 14 individual samples were found to be 
RNA positive, given the parameters. Incidence for the 2-stage procedure is calculated 
as given in equation (2.5); with an estimate of 26.83 (CI: 24.40%-29.26%). 
 
Table 4.4: Estimated 2-stage incidence estimates when true incidence=0.15 
 =28; I =0.15   
Parameters True Prevalence Incidence (CI) 
Tests 
required 
Pool size =100 N=1000  25 26.83 (24.40-29.26) 650 
 
30 25.12 (22.78-27.46) 595 
 
35 25.12 (22.71-27.54) 607 
Pool size =100 N=2000 25 34.83 (32.41-37.25) 1396 
 
30 20.81 (19.47-22.15) 1215 
 
35 25.12 (23.44-26.81) 1214 
Pool size =100 N=5000  25 26.17 (25.13-27.22) 3338 
 
30 28.33 (27.15-29.51) 3236 
 35 31.27 (29.87-32.66) 3048 
Pool size =20 N=1000 25 27.01 (23.70-30.32) 298 
 
30 42.63 (38.05-47.21) 375 
 35 42.52 (37.81-47.24) 353 
Pool size =50 N=1000 25 28.33 (25.73-30.93) 507 
 
30 32.26 (29.25-35.26) 502 
 35 37.67 (34.11-41.24) 513 
 
It should be noted that the confidence intervals obtained for the dual stage algorithm 
has been „corrected‟ for pooling as suggested in equation 2.13. 
 
We observe that when sample size is held constant at 1,000 and pool size varied, the 
differences in incidence estimates are very similar when the true prevalence is at 25%. 
For instance, when the pool size is 100, 20 and 50 the incidence estimates are 26.83% 
(95% C.I 24.40-29.26), 27.01% (95% C.I 23.70-30.32) and 28.33% (95% C.I 25.73-
30.93) respectively. 
Whereas, given the same specification and the true prevalence of either 30% or 35 %, 
results indicate that the variation in the incident estimates become more prominent. In 
general, incidence estimates tend towards the true value with an increase in pool sizes. 
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With sample sizes varied between 1000 and 5000,  =28; I =0.15 and pool size =100, 
it can be seen from Table 4.4 that a moderate sample size of 2000 and a true 
prevalence value of 30 % gave the lowest incidence value and the highest value was 
obtained for the case where prevalence was 25% with the same sample size. 
Otherwise the incidence values are fairly consistent even with sample size varied. 
Confidence intervals tend to be relatively close to the true incidence value unlike the 
estimates in Table 4.3. 
 
4.4.2 ASSUMING INCIDENCE OF 0.12 
 
The estimates in Table 4.5 show a considerable difference when true incidence is set 
at 0.15 compared to 0.12.  
 
Table 4.5: Estimated 2-stage incidence estimates when true incidence=0.12 
 =28; I =0.12  
Parameters True Prevalence Incidence CI 
Tests 
required 
Pool size =100 N=1000  25 17.95 (16.34-19.55) 547 
 
30 25.12 (22.77-27.47) 591 
 35 25.12 (22.70-27.54) 607 
Pool size =100 N=2000  25 26.00 (24.34-27.66) 1293 
 
30 25.12 (23.48-26.76) 1213 
  35 25.12 (23.43-26.81) 1214 
Pool size =100 N=5000  25 21.87 (21.01-22.73) 3138 
 
30 25.48 (24.44-26.52) 3136 
  35 30.89 (29.51-32.26) 3033 
Pool size =20 N=1000  25 22.79 (19.79-25.80) 257 
 
30 32.87 (28.99-36.76) 315 
  35 38.91 (34.46-43.37) 333 
Pool size =50 N=1000  25 23.67 (21.41-25.93) 454 
 
30 32.26 (29.24-35.27) 498 
  35 30.37 (27.42-33.32) 463 
 
When the true incidence is set at 12%, sample size held constant at 1000, the lowest 
estimate of incidence is observed when the true prevalence is 25% and pool size is 
100. Estimates of incidence when samples were pooled in groups of 20 and 50 were 
very similar compared to when they were grouped into pools of size 100 for the same 
sample size (1000). Again we observe that the differences in incidence estimates are 
minimal when the prevalence is at 25% with varying pool sizes at a sample size of 
1000.  
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From Table 4.5, incidence estimates are the same when the true prevalence is 30% or 
35%, with a varying sample size of 1000 and 2000. However, when the sample size 
increases to 5000, there are differences between the estimates. In proportion to sample 
size, the total numbers of tests required are least for pool sizes of 20 and 50 when 
sample size is constant at 1000. The values of these estimates are lower than when the 
incidence was set at 0.15. 
 
4.5 MULTI STAGE ALGORITHM (3-STAGE POOLING) 
 
The differences in estimates for between the 1 stage (individual samples), 2 stage and 
3 stage algorithms are examined and discussed. Similarities in their confidence 
intervals are also mentioned and highlighted. 
 
Table 4.6: Estimated 3 Stage incidence estimates when pool size=100:20:5 
  
True 
Prevalence Incidence CI 
No of tests 
required 
Multi Stage 
Sample size=1000; I=0.12 25% 20.01 (8.27-31.74) 130 
 
30% 32.03 (16.52-47.54) 169 
 
35% 36.39 (19.32-53.45) 174 
Sample size=1000,I=0.13 25% 21.86 (9.59-34.13) 135 
 
30% 34.09 (18.09-50.09) 178 
 
35% 38.60 (21.02-56.18) 183 
Sample size=1000, I=0.15 25% 25.58 (12.31-38.85) 155 
 
30% 40.31 (22.90-57.72) 197 
 35% 43.12 (24.51-61.72) 197 
 
Table 4.6 displays the results of the multistage algorithm for estimating incidence.  
Taking the scenario of assumed prevalence of 25% and a sample size of 1,000; the 
number of positive samples on the simulated ELISA test was 261, while the negative 
samples were 739. The negative sample (739) samples are then grouped into 7 pools 
of 100, with the 8
th
 pool containing only 39 samples; since it was incomplete. This 
step will be regarded as stage 1 where 7 pools of 100 samples each are formed. 
Results show that 6 of the 7 pools are positive. Thus in the next stage, the 600 
samples are pooled into groups of 20, giving 20 pools of 30 samples each. It should be 
noted that the 39 extra samples from stage 1 are not included in the next stage. They 
will be retested alongside the other (if any) incomplete samples at the end of the 
procedure. Results from the 2
nd
 stage show that 10 out of the 20 pools are positive and 
it is these 200 samples that will be tested again in the 3
rd
 and final stage. In stage 3, 
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200 samples are divided into 40 groups of 5 and each of the 40 groups is tested. 11 of 
these pools are positive, thus 55 samples were each tested individually. Therefore, the 
total amount of tests required for this simulation was 8+27+40+55; which gives 130 
tests in total. Incidence is calculated as given in equation (2.10); with an estimate of 
20.01 (CI: 8.27%-31.74%). 
 
From the results, we observe that the lower the true prevalence, the lower the number 
of tests required in estimating incidence. Even though the incidence estimates 
fluctuate slightly, the lower bounds of the confidence interval for low prevalence 
(25%) captures the value of the true incidence. 
 
4.6 EFFICIENCY OF POOLING ALGORITHMS (2 STAGE AND    
3 STAGE)  
 
For given values of prevalence ( p ), the optimally efficient 2-stage and 3-stage 
procedure is determined by the value of n that minimizes equation (3.1) and (3.2) 
above. The relative efficiency and accuracy of the pooling strategies for assumed 
prevalence rates are demonstrated in Table 4.7.  The efficiency of a pooling algorithm 
is defined as the expected number of tests required per individual specimen evaluated, 
ignoring confirmatory retesting of individual positive specimens (Westreich et al, 
2008). Therefore an efficiency of less than „1‟ indicates that the pooling algorithm 
will require a lesser amount of tests on the average, than individual tests.  
 
Figure 4.1 shows the expected number of tests per individual sample at various group 
sizes ranging from 10 to 500.  A group size of „1‟ represents individual testing. The 
shapes of the relative cost curve vary for the different prevalence rates above.  For a 
prevalence rate of 0.01% and a group size of 50, we will only require 41% as many 
tests as individual testing for a 2 stage algorithm and 14% of tests for a 3 stage 
algorithm. When the prevalence is at 0.1%, the 2-stage algorithm shows a 6% 
decrease for group sizes of 20. 
  
For group sizes of 200, with the same prevalence rates of 0.01% and 0.1%, S2 shows 
19 % efficiency compared to individual testing while S3 shows 3% efficiency, 
respectively. When the prevalence is higher, at 25% for instance, both the 2-stage and 
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3-stage algorithms show 100% efficiency for groups of 10 and 20. We also note that 
as prevalence increases, efficiency between both algorithms show substantial 
differences. 
 
          
             
        
 Figure 4.1: Expected number of tests for 2 stage and 3 stage algorithms at given 
prevalence rates. S2 is a 2-stage “Dorfman Algorithm” while S3 is the 3-stage 
/Multistage Algorithm. 
 
The 3-stage algorithm consistently shows a lower efficiency across all the given 
prevalence rates showing that the more stages involved the more significant the 
results. As group sizes increase, the expected numbers of tests decrease. 
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The asymptotic relative efficiency (ARE) of pˆ after k stages relative to individual 
testing of each specimen is computed. The asymptotic efficiency is defined as the 
ratio of the variance with individual testing 
(1 )p p
N

divided by the variance with 
multistage and is given by:  
1
(1 )
(1 (1 ) )
k
k
c
k
c
c p p
p


 
                               (4.1) 
 
Table 4.7 illustrates the relative efficiency for an arbitrary range of prevalence values 
after each stage of a multistage pooling study, given a sample of N=1000 and initially 
sub divided groups of 100. 
 
Table 4.7: Asymptotic efficiency of pˆ after 3 stages relative to individual testing 
    Prevalence 
Stage Pool size 0.0005 0.01 0.02 0.04 
1 100 0.98 0.58 0.31 0.07 
2 10 1 0.96 0.91 0.83 
3 1 1 1 1 1 
 
At the end of the stage 2, if p=0.0005 pˆ is nearly as efficient as individual testing as 
shown in the table (ARE=0.98). When p =0.01 the multistage estimator is about half 
as efficient as individual testing (ARE=0.53). 
 
4.7 COST COMPARISON OF POOLING ALGORITHMS 
 
One major advantage of pooling studies over individual testing is cost savings. The 
cost of administering an RNA test to an individual is $119 (R952 at the exchange rate 
of R8 to $1). Cost is calculated directly and does not take into account other costs like 
the actual cost of pooling each blood sample, value of the cost kit, labour and cost of 
retesting the pool if positive. 
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Tables 4.8, 4.9 and 4.10 show the cost savings associated with each pooling scheme 
when compared to individual testing of all samples. The comparison is done for 
different sample sizes, holding the pool sizes constant.  
 
Table 4.8: Cost savings when sample size =1000 
N=1000,  2 stage k=100, 3 stage k=100:20:5 
Prevalence 25% 30% 35% 
Cost to test all specimens R 703,528 R 651,168 R 613,088 
Cost to test 2-stage R 520,744 R 562,632 R 577,864 
Cost to test 3-stage R 123,760 R 160,888 R 165,648 
Cost reduction-2stage vs ALL 26% 14% 6% 
Cost reduction-3stage vs ALL 82% 75% 73% 
Cost reduction-3stage vs 2 Stage 76% 71% 71% 
 
Table 4.8 shows the results of cost savings of direct estimation compared to two 
pooled scenarios, when sample size is 1000. As expected, multistage pooling shows a 
considerable amount of savings in cost compared to the 2 stage pooling, and 
compared to individual testing of all specimens. At a true prevalence of 25%, there is 
an 82% savings on cost compared to individual testing, and a 76% savings when 
comparing multistage to 2-stage pooling.  For the same parameters, there is only a 
26% reduction in cost when comparing the 2 stage pooling to individual testing of all 
specimens. 
Table 4.9: Cost savings when sample size=2000  
N=2000,  2 stage k=100, 3 stage k=100:20:5 
Prevalence 25% 30% 35% 
Cost to test all specimens R 1,407,056 R 1,331,848 R 1,256,640 
Cost to test 2-stage R 1,230,936 R 1,154,776 R 1,155,728 
Cost to test 3-stage R 277,032 R 295,120 R 317,016 
Cost reduction-2stage vs ALL 13% 13% 8% 
Cost reduction-3stage vs ALL 80% 78% 75% 
Cost reduction-3stage vs 2 Stage 77% 74% 73% 
 
Table 4.10: Cost savings when sample size =5000 
N=5000,  2 stage k=100, 3 stage k=100:20:5 
Prevalence 25% 30% 35% 
Cost to test all specimens R 3,596,656 R 3,406,256 R 3,140,648 
Cost to test 2-stage R 2,987,376 R 2,985,472 R 2,887,416 
Cost to test 3-stage R 592,144 R 295,120 R 317,016 
Cost reduction-2stage vs ALL 17% 12% 8% 
Cost reduction-3stage vs ALL 84% 91% 90% 
Cost reduction-3stage vs 2 Stage 80% 90% 89% 
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CHAPTER 5 : SUMMARY AND CONCLUSIONS 
 
5.1 SUMMARY 
 
Estimates of HIV incidence are traditionally obtained from cohort studies which are 
time consuming and cost prohibitive. This report focused on an alternative to 
estimating HIV incidence from a cross-sectional sample without the disadvantages 
associated with the cohort study.  
 
Chapter 1 gives an introduction of the epidemic in South Africa and an overview of 
the incidence and prevalence which are measures of the magnitude and rate of new 
infections of the disease. In Chapter 2, a literature review of the methods of estimating 
incidence is provided, along with an introduction to the pooling technique. Chapter 3 
discusses the operating characteristics, pooling assumptions, the simulation algorithm 
used and the parameters used in the simulation model. In Chapter 4, estimates of 
incidence are calculated by direct estimation and using varying pool sizes and sample 
sizes.  The accuracy of pooling blood samples was discussed along with the cost 
savings associated with different pooling strategies. 
 
Incidence estimates calculated using the relationship between prevalence and mean 
duration of recent infection are compared to estimates derived from group testing 
procedures.  
The results show that estimates from the pooled testing procedures are similar to, but 
more precise than the direct testing approach. In Table 4.3 for instance, with a sample 
of 1000, and a given prevalence of 25%; incidence was calculated as 19.4% (CI: 
9.72%-34.51%). Using the same criteria the 2-stage algorithm yielded a 17.95% 
estimate (CI: 16.34%-19.55%); while the 3-stage algorithm resulted in a 20.01% 
incidence estimate (CI: 8.27%-31.74%). 
 
For pooled testing, the findings suggest that for same number of samples, pooled 
testing provides a decrease in the average number of tests required per specimen, 
compared to individual testing.  This is reflected in the charts in Figure 4.1, which 
shows gains in efficiency for both 2-stage and 3-stage algorithms, compared to 
individual testing. The findings also reveal that the 3-stage algorithm consistently 
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offers a lower efficiency compared to its 2-stage counterpart; implying that as group 
sizes increase, the expected numbers of tests decreases, thereby saving time and 
money. 
To further emphasize the benefits of pooling, a cost comparison of the different 
strategies is highlighted in the results. Tables 4.7 to 4.9 show that in terms of cost, 
there is up to 80% reduction in the cost of testing going from individual testing to 
multiple stage testing; and up to 70% reduction in cost going from single stage testing 
to multiple stage testing. These results just further show that there is substantial cost 
savings involved in pooled testing, regardless of the number of stages involved. 
 
5.2 CONCLUSION 
 
Estimating HIV incidence from methods like cohort studies and back calculation is 
currently difficult to perform. The findings from this study show that laboratory 
methods like the pooled testing procedure holds great advantages over either of the 
above mentioned methods. The precision of the estimates obtained with both pooled 
testing algorithms is shown to be better than individual testing, as well as being closer 
to the true incidence. This conclusion is further reinforced by the narrow width of the 
confidence intervals in both pooling algorithms compared to individual testing. 
Findings suggest that incidence estimates derived from pooled testing are precise, cost 
saving and time saving compared to individual testing 
 
5.3 RECOMMENDATIONS 
 
In the current study, one of the assumptions applied was that the sensitivity of the test 
for a pool is approximately the same as it is for an individual sample. It would be of 
interest to introduce the implication and effect of test errors into the study like the 
modeling of sensitivity and specificity as a function of pool size. This will give an 
indication as to whether more precise estimates of incidence can be derived, and will 
examine the issue of dilution effects more closely. 
 
Further investigations or research into the application of the pooling method to 
estimate incidence should include a matrix based approach, mentioned briefly in 
Chapter 2.3.1.  The comparison of this method to other multistage pooling strategies 
can be undertaken to determine which is more efficient and optimal. 
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Data on the incidence of HIV in South Africa, and Africa in general is still limited and 
insufficient. However, with an introduction of pooled testing strategies, the 
disadvantages can be minimized significantly. The integration of pooled studies into 
the estimation of HIV incidence in South Africa will be cost effective thus allowing 
money saved to be spent in other areas of researching the HIV Virus. Pooled testing 
will also enable the monitoring of the virus to be feasible and to limit the development 
and transmission of HIV in resource constrained settings. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
50 
 
REFERENCES: 
 
Abdool Karim, Q. and Abdool Karim, S.S. (1999), South Africa: Host to a new and 
emerging HIV epidemic, Sexually Transmitted Infections, 75, pp. 139-147. 
 
Bacchetti, P., Segal, M.R., and Jewell, N.P. (1993), Back calculation of HIV Infection 
Rates, Statistical Science, 8 (2), pp. 82-101. 
 
Beyrer, C., Brookmeyer, R., Natpratan, C., Kunawararak, P., Niraroot, V., Palapunya, 
P., Khamboonruang, C., Celentano D. and Nelson K. (1996), Measuring HIV-1 
Incidence in Northern Thailand: Prospective Cohort Results and Estimates Based on 
Early Diagnostic Tests. Journal of Acquired Immune Deficiency Syndromes, 12 (5), 
pp. 95-499. 
 
Brookmeyer, R. (1991), Reconstruction and Future Trends of the AIDS Epidemic in 
the United States, Science, 253, pp. 37-42. 
 
Brookmeyer, R. (1996), AIDS, Epidemics and Statistics, Biometrics, 52, pp. 781-796. 
 
Brookmeyer, R. (1997), Accounting for follow-up bias in estimation of Human 
Immunodeficiency Virus Incidence Rates, Journal of the Royal Statistical Society, 
160 (1), pp. 127-140. 
 
Brookmeyer, R. (1999), Analysis of Multistage Pooling Studies of Biological 
Specimens for Estimating Disease Incidence and Prevalence, Biometrics, 55, pp. 608-
612. 
 
Brookmeyer, R. and Quinn, T. (1995), Estimation of Current Human 
Immunodeficiency Virus Rates from a Cross-Sectional Survey Using Early 
Diagnostic Tests, American Journal of Epidemiology, 141(2), pp. 166-172. 
 
Brookmeyer, R., Quinn, T., Shepherd M., Mehendale S., Rodrigues J. and Bollinger 
R. (1995), The AIDS Epidemic in India: A New Method for Estimating Current 
Human Immunodeficiency Virus (HIV) incidence rates, American Journal of 
Epidemiology, 142 (7), pp. 709-713. 
 
Cleghorn, F.R., Jack, N., Murphy, J.R., Edwards, J., Mahabir, B., Paul, R., O‟Brien, 
T., Greenberg, M., Weinhold, K., Bartholomew, C., Brookmeyer, R., and Blattner, 
W.A. (1998), Direct And Indirect Estimates of HIV-1 incidence in a High Prevalence 
Population, American Journal of Epidemiology, 147, pp. 834-839. 
 
Chen, C.L. and Swallow, W.H. (1990), Using Group Testing to Estimate a Proportion, 
and To Test the Binomial Model, Biometrics, 46 (4), pp. 1035-1046. 
 
Cole, S.R., Chu, H., Brookmeyer, R. (2006), Confidence Intervals for Biomarker-
based Human Immunodeficiency Virus Incidence Estimates and Differences using 
Prevalent Data, American Journal of Epidemiology, 165, pp. 94-100. 
 
51 
 
Constantine, N. (2001), HIV Antibody Assays. HIV InSite Knowledge Base Chapter. 
http://hivinsite.ucsf.edu/InSite?page=kb-02&doc=kb-02-02-01. 
 
Cowling, D.W., Gardner, I.A. and Wesley, J.O. (1999), Comparison of Methods for 
Estimation of Individual Level Prevalence based on Pooled Samples, Preventive 
Veterinary Medicine, 39, pp. 211-225. 
 
Department of Health (2007), The National HIV and Syphilis Prevalence Survey in 
South Africa, 2007.  Pretoria: South African Department of Health; 2008. 
 
Dorfman, R. (1943), The Detection of Defective Members of Large Populations, The 
Annals of Mathematical Statistics, 14 (4), pp. 436-440. 
 
Emmanuel, J. C., Bassett, M. T., Smith, H. J., Jacobs, J. A. (1988), Pooling of sera for 
human immunodeficiency virus (HIV) testing: An economic method for use in 
developing countries, Journal of Clinical Pathology, 41, pp. 582–585. 
 
Gilbert, L. and Walker, L. (2002), HIV/AIDS in South Africa: An Overview, Cad. 
Saúde Pública, 18(3), pp. 651-660. 
 
Gilgen, D., Campbell, C., Williams, B., Taljaard, D. and Macphail, C. (2000), The 
Natural History of HIV/AIDS in South Africa: A Biomedical and Social Survey in 
Carletonville. Johannesburg: Council for Scientific and Industrial Research. 
 
Gouws, E., Williams, B.G., Sheppard, H.W., Barryett, E., and Abdool Karim, S. 
(2002), High Incidence of HIV-1 in South Africa Using a Standardised Algorithm for 
Recent Seroconversion, Journal of Acquired Immune Deficiency Syndromes, 29(5), 
pp. 531-535. 
 
Grimes, D.A., and Schulz, K.F. (2002), An overview of clinical research: the lay of 
the land, The Lancet, 359, pp. 57-61. 
 
Gupta, D. and Malina, R. (1999), Group Testing in Presence of Classification Errors, 
Statistics in Medicine, 18, pp. 1049-1068. 
 
Hauck, W.W. (1991), Confidence intervals for Seroprevalence Determined from 
Pooled Sera, Biostatistics Technical Report #5, pp. 1-11. 
 
Hecht, M.F., Busch, M.P., Rawal, B., Webb, M., Rosenberg, E., Swanson, M., 
Chesney, M., Anderson, J., Levy, J., and Kahn, J.O. (2002), Use of Laboratory Tests 
and Clinical Symptoms for Identification of Primary HIV Infection, Journal of 
Acquired Immune Deficiency Syndromes, 16, pp. 1119-1129. 
 
Hung, M. and Swallow, W.H. (2000), Use of Binomial Group Testing in Tests of 
Hypotheses for Classification or Quantitative Covariables, Biometrics, 56(1), pp. 204-
212. 
 
Janssen, R.S., Satten, G.A., Stramer, S.L., Rawal, B.D., O‟Brien, T.R., Weiblen, B.J, 
Hecht, F.M., Jack, N., Cleghorn, F.R., Kahn, J.O., Chesney, M.A., Busch, M.P. 
(1998),  New Testing Strategy to Detect Early HIV-1 Infection for Use in Incidence 
52 
 
Estimates and for Clinical and Prevention Purposes, Journal of the American Medical 
Association, 280(1), pp. 42-48. 
 
Johnson, N. L., Kotz, S. and Wu, X. (1991), Inspection Errors for Attributes in 
Quality Control. New York: Chapman and Hall Ltd. 
 
Johnson, W.O., and Gastwirth, J.L. (2000), Dual Group Screening, Journal of 
Statistical Planning and Inference, 83, pp. 449-473. 
 
Kamanga, G., Thumbi, P., Nkhoma, M., Manamela, P., Bogoshi, M., Latka, M., 
Martinson, F., Karim, S.S.A., Kumwenda, J., Rees, H., Churchyard, G., McCauley, 
M., Gay, C., Cohen, M.S. (2008), High prevalence of acute HIV infection in Sub-
Saharan Africa: a cross-sectional, multi-centre screening study, Abstract XVII 
International AIDS Conference, Mexico City. 
 
Kaplan, E.H., and Brookmeyer, R. (1999), Snapshot Estimators of Recent HIV 
incidence Rates, Operations Research, 47(1), pp. 29-37. 
 
Kaplan, E.H., Kedem, E., and Pollack, S. (1998), HIV Incidence in Ethiopian 
Immigrants to Israel, Journal of Acquired Immune Deficiency Syndrome, 17, pp. 465-
469. 
 
Kennedy, N.L. (2004a), Multistage Group Testing Procedure (Group Screening), 
Communications in Statistics, 33 (3), pp. 621-637. 
 
Kennedy, N.L. (2004b), Testing For the Presence of Disease by Pooling Samples, 
Australian and New Zealand Journal of Statistics, 46(3), pp. 383–390. 
 
Kim, H., Hudgens, M.G., Dreyfuss, J.M., Westreich, D.J., Pilcher, C.D. (2007), 
Comparison of Group Testing Algorithms for Case Identification in the Presence of 
Test Error, Biometrics, 63, pp. 1152-63. 
 
Kline, R. L., Brothers, T. A., Brookmeyer, R., Zeger.  S., and Quinn, T.C. (1989), 
Evaluation of Human Immunodeficiency Virus Seroprevalence in Population Surveys 
Using Pooled Sera, Journal of Clinical Microbiology, 27(7), pp. 1449-1452. 
 
Kral, A.H., Lorvick, J., Gee, L., Bacchetti, P., Rawal, B., Busch, M., and Edlin, B.R. 
(2003), Trends in Human Immunodeficiency Virus Seroincidence among Street-
Recruited Injection Drug Users in San Francisco, 1987-1998, American Journal of 
Epidemiology, 157, pp. 915-922. 
 
Le Corfec, E., Le Pont, F., Tuckwell, H.C., Rouzioux, C., and Costagliola, D. (1999), 
Direct HIV Testing in Blood Donations: Variation of the Yield with Detection 
Threshold and Pool Size, Transfusion, 39, pp. 1141-1144. 
 
Lehmann, E. L. (1999), Elements of Large-Sample Theory. New York: Springer-
Verlag. 
 
53 
 
Le Vu, S., Pillonel, J., Semaille, C., Bernillon, P., Le Strat, Y., Meyer,L., and 
Desenclos, J.C. (2008), Principles and uses of HIV incidence estimation from recent 
infection testing- A review. Eurosurveillance, 13 (7–9), pp. 11-16. 
 
Litvak, E., Tu, X.M., and Pagano, M. (1994), Screening for the Presence of a Disease 
by Pooling Sera Samples, Journal of the American Statistical Association, 89(426), 
pp. 424-431. 
 
Maherchandani, S., Munoz-Zanzi, C.A., Patnayak, D.P., Malik, Y.S. and Goyal, S.M. 
(2004), The effect of pooling sera on the detection of avian pneumovirus antibodies 
using an enzyme-linked immunosorbent assay test, Journal of Veterinary Diagnostic 
Investigation, 16, pp. 497–502. 
 
McDougal, J.S., Pilcher, C.D., Parekh, B.S., Gershy-Damet, G., Branson, B.M., 
Marsh, K. and Wiktor, S.Z. (2005), Surveillance for HIV-1 incidence using tests for 
recent infection in resource–constrained countries, Journal of Acquired Immune 
Deficiency Syndromes, 19, S25-S30. 
 
Munoz-Zanzi, C.A., Johnson, W.O., Thurmond, M.C., and Hietala S.K. (2000), 
Pooled-sample testing as a herd-screening tool for detection of bovine viral diarrhea 
virus persistently infected cattle, Journal of Veterinary Diagnostic Investigation, 12, 
pp. 195–203. 
 
Nelson, L.J. (2005), Current Status and Future of HIV Surveillance. Joint working 
group meeting, HIV and Drug Resistance Surveillance and Testing, Versailles, 
October 2005. 
 
Parekh, B.S. and McDougal, J. S (2001), New Approaches for Detecting Recent HIV-
1 Infection, AIDS Review, 3, pp. 183-193. 
 
Parekh, B.S. and McDougal, J.S. (2005), Application of laboratory methods for 
estimation of HIV-1 incidence, Indian Journal of Medical Research, 121, pp. 510-
518. 
 
Pettifor, A., Macphail, C., Rees, H. And Cohen, M. (2008), HIV and Sexual 
Behaviour among Young People: The South African Paradox, Sexually Transmitted 
Diseases, 35(10), pp. 843–844. 
 
Philippe, P. (2001), Density Incidence and Cumulative Incidence: A Fundamental 
Difference. The Internet Journal of Internal Medicine, 2, pp. 1-3. 
 
Pilcher, C. D., McPherson, J. T., Leone, P. A., Smurzynski, M., Owen-O'Dowd, J., 
Peace-Brewer, A. L., Harris, J., Hicks, C. B., Eron, J. J. and Fiscus, S. A. (2002),  
Real-time, universal screening for acute HIV infection in a routine HIV counselling 
and testing population, Journal of the American Medical Association, 288, pp. 216-
221. 
 
 
 
54 
 
Pilcher, C. D., Price, M. A., Hoffman, I. F., Galvin, S., Martinson, F. E., Kazembe, P. 
N., Eron, J. J., Miller, W. C., Fiscus, S. A., and Cohen, M. S. (2004), Frequent 
detection of acute primary HIV infection in men in Malawi, Journal of Acquired 
Immune Deficiency Syndromes, 18, pp. 517–524. 
 
Pilcher, C. D., Fiscus, S. A., Nguyen, T. Q., Foust, E., Wolf, L., Williams, D., Ashby, 
R., O'Dowd, J. O., McPherson, J. T., Stalzer, B., Hightow, L., Miller, W. C., Eron, J. 
J. and Cohen, M.S. (2005), Detection of acute infections during HIV testing in North 
Carolina, New England Journal of Medicine, 352, pp. 1873–1883. 
 
Quinn, T.C., Brookmeyer, R., Kline, R., Shepherd, M., Paranjape, R., Mehendale, S., 
Gadkari, D.A., and Bollinger, R. (2000),  Feasibility of pooling sera for HIV-1 viral 
RNA to diagnose acute Primary HIV-1 infection and estimate HIV incidence, Journal 
of Acquired Immune Deficiency Syndromes, 14, pp. 2751-2757. 
 
Ramjee G., Abdool Karim S. S. and Sturm A. W. (1998), Sexually transmitted 
infections among sex workers in KwaZulu-Natal, South Africa. Journal of Sexually 
Transmitted Diseases, 25, pp. 346-349. 
 
Rosenberg, E. (2002), Backgrounder: Recognizing and diagnosing primary HIV 
infection. Research Initiative Treatment Action (RITA), 7(2), pp. 5-10. 
 
Rutherford, G.W., Schwarcz, S.K., and McFarland, W. (2000), Surveillance for 
Incident HIV Infection: New Technology and New Opportunities, Journal of 
Acquired Immune Deficiency Syndromes, vol. 25, pp. S115-S119. 
 
Salomon, J.A. and Murray, CJL. (2001), Modelling HIV/AIDS epidemics in sub-
Saharan Africa using seroprevalence data from antenatal clinics, Bulletin of the World 
Health Organization, 79(7) pp. 596-607. 
 
SAS® Institute Inc. (2004), SAS User's Guide, Version 9.1, Cary, NC: SAS Institute 
Inc. 
 
Saraniti B.A. (2006), Optimal pooled testing, Health Care Management Science, 9, 
pp. 143–149. 
 
Satten, G.A., Janssen, R., Busch, M.P., and Datta, S. (1999), Validating Marker-
Based Incidence Estimates in Repeatedly Screened Populations,  Biometrics, 55, pp. 
1224-1227. 
 
Sergeant, E. and Toribio, J. (2004), Estimation of Animal-Level Prevalence from 
Testing of Pooled Samples, A report prepared for The Australian Bio security 
Cooperative Research Centre for emerging infectious diseases.  
 
Shisana, O. and Simbayi, L. (2002), Nelson Mandela/HSRC Study of HIV/AIDS: 
South African National HIV Prevalence Behavioural Risks and Mass Media 
Household Survey Cape Town, South Africa: Human Sciences Research Council. 
 
 
 
55 
 
Shisana, O., Rehle, T., Simbayi, L.C., Parker, W., Zuma, K., Bhana, A., Connolly, C., 
Jooste, S. and Pillay, V. (2005), South African National HIV Prevalence, HIV 
Incidence,Behaviour and Communication Survey Cape Town, South Africa: Human 
Sciences Research Council Press. 
 
Stevens, W., Akkers, E., Myers, M., Motloung, T., Pilcher, C. and Venter, F. (2005), 
High prevalence of undetected, acute HIV infection in a South African primary care 
clinic, abstract MoOa0108. The Third IAS Conference on HIV Pathogenesis and 
Treatment. International AIDS Society, Rio de Janeiro, Brazil. 
 
Thompson, K. H. (1962), Estimation of the proportion of vectors in a natural 
population of insects. Biometrics, 18, pp. 568-578. 
 
UNAIDS (2008), Report on the Global AIDS Epidemic.  
 
Wein, L.M. and Zenios, S.A. (1996). Pooled testing for HIV screening: Capturing the 
Dilution Effect, Operations Research, 44, pp.543–569. 
 
Welz, T., Hosegood, V., Jaffar, S., Bätzing-Feigenbaum, J., Herbst, K. and Newell, 
M. (2007). Continued very high prevalence of HIV infection in rural KwaZulu-Natal, 
South Africa: A population based longitudinal study, AIDS, 21, pp 1467–1472. 
 
Westreich, D.J., Hudgens, M.G., Fiscus, S.A., and Pilcher, C.D. (2008). Optimizing 
Screening for Acute Human Immunodeficiency Virus Infection with Pooled Nucleic 
Acid Amplification Tests, Journal of Clinical Microbiology, vol.46, No.5, pp1785-
1792. 
 
Williams, B.G., and Gouws, E. (2001). The Epidemiology of Human 
Immunodeficiency Virus in South Africa, Philosophical Transactions of the Royal 
Society of London, B., 356, pp.  1077-1086. 
 
Williams, B.G., Gouws, E., Wilkinson, D. and Abdool Karim, S. (2001), Estimating 
HIV incidence rates from age prevalence data in epidemic situations, Statistics in 
Medicine, 20, pp. 2003-2016. 
 
Xie, M., Tatsuoka, K., Sacks, J. and Young, S.S. (2001). Group testing with blockers 
and synergism, Journal of the American Statistical Association 96, pp92-102. 
 
Zenios, S. A. and Wein, L. M. (1998). Pooled testing for HIV prevalence estimation: 
Exploiting the dilution effect, Statistics in Medicine 17, pp.1447–1467. 
 
 
 
